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Abstract 
Chronic pain is a global public health challenge, affecting nearly one third of adults 
worldwide. Current treatments are inadequate, especially since some of the mainstay therapies 
(e.g. opioids, NSAIDs) are often ineffective and/or associated with significant toxicity. The 
solution to these problems requires an improved understanding of chronic pain pathology, 
particularly the role that the brain plays in causing or amplifying pain perception, and how 
analgesic intervention might target these brain-based mechanisms. This dissertation aims to 
identify brain network alterations in fibromyalgia (FM), a common and canonical chronic pain 
condition with presumed CNS pathology, and determine how non-invasive brain stimulation may 
target aberrant brain network connectivity to promote analgesia.  
Across a wide range of diverse neurological disorders, hubs (i.e. highly connected brain 
regions) appear to be disrupted and the character of this disruption can yield insights into the 
pathophysiology of these disorders.  In Chapter 2, we describe the application of a brain network 
based approach to examine hub topology in FM patients compared to healthy volunteers. We 
identified significant disruptions in hub rank order in FM patients. In FM, but not controls, the 
anterior insula was a hub with significantly higher inter-modular connectivity and membership in 
the rich club (a functional backbone of connectivity formed by highly interconnected hubs). 
Among FM patients, rich club membership varied with the intensity of clinical pain: the 
posterior insula, primary somatosensory and motor cortices belonged to the rich club only in FM 
patients with the highest pain.  Further, we found that the eigenvector centrality (a measure of 
how connected a brain region is to other highly connected regions) of the posterior insula 
	   xii	  
positively correlated with clinical pain, and mediated the relationship between levels of 
glutamate + glutamine within this structure and the patient’s subjective clinical pain report.  
Together, these findings demonstrate an altered hub topology in FM and are the first to suggest 
that disruptions in the excitatory tone within the insula could alter the strength of the insula as a 
hub and subsequently lead to increased clinical pain.  
Transcranial direct current stimulation (tDCS) has emerged as an attractive noninvasive 
treatment for pain, given its ability to target specific cortical regions with relatively few side 
effects.  Motor cortex (M1) tDCS relieves pain in FM, but the analgesic mechanism remains 
unknown. In Chapter 3, we measured changes in resting state functional connectivity after sham 
and real M1 tDCS in twelve FM patients and examined if these changes were related to 
subsequent analgesia.  M1 tDCS (compared to sham) reduced pro-nociceptive functional 
connectivity, specifically between the motor and sensory nuclei of the thalamus and multiple 
cortical regions, including primary motor and somatosensory areas. Interestingly, decreased 
connectivity between the thalamus and posterior insula, M1 and somatosensory cortices 
correlated with reductions in clinical pain after both sham and active treatment. These results 
suggest that while there may be a placebo response common to both sham and real tDCS, 
repetitive M1 tDCS causes distinct changes in functional connectivity that last beyond the 
stimulation period and may produce analgesia by inhibiting pro-nociceptive thalamic 
connectivity. 
This research offers new insight into the neurobiology of chronic centralized pain 
conditions and contributes to the understanding of how non-invasive brain stimulation causes 
analgesia. This knowledge could lead to more informed stimulation sites and personalized 
treatment based on network connectivity in each individual patient. 
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Chapter 1 : Introduction 
Chronic pain is a global public health challenge.  Nearly one third of adults worldwide 
suffer from a chronic pain condition (Elzahaf et al., 2012). In the United States, 116 million 
Americans suffer from chronic pain, which is more than heart disease, cancer and diabetes 
combined. At a cost of $560-635 billion annually, chronic pain is arguably the most prevalent 
and costly public health crisis in America today (Institute of Medicine (US) Committee on 
Advancing Pain Research, Care, and Education, 2011).  
Pain is a multidimensional, conscious experience that is shaped by environmental, 
psychological and biological factors unique to an individual.  Nociception is an unconscious 
physiological process reflecting the activity of specialized sensory receptors (nociceptors) in the 
periphery that respond to a noxious stimulus and transmit this information to the central nervous 
system (CNS). Nociception is neither a necessary, nor sufficient, cause of pain. Pain, on the other 
hand, is a complex emotional and cognitive experience primarily generated by the brain, and 
may or may not be correlated with actual tissue damage (Merskey H, 1994; Tracey, 2005).  
The transition from acute to chronic pain (defined as persistent symptoms for more than 
three months) is not well understood but functional, structural and neurochemical abnormalities 
observed in the CNS of chronic pain patients point to central mechanisms in some individuals.  
Centralized pain, in this context, refers to dysfunction in CNS processing that causes, amplifies 
or sustains the perception of pain (Sluka and Clauw, 2016) in a way that is distinct or even 
disconnected from peripheral nociceptive events.  Fibromyalgia (FM) is a common chronic 
centralized pain condition, affecting 2-8% of the population (Wolfe et al., 1995; McBeth and 
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Jones, 2007; Vincent et al., 2013). It is considered the canonical centralized pain disorder, 
although other chronic pain disorders (i.e. irritable bowel syndrome, temporomandibular joint 
syndrome, chronic lower back pain) may share underlying pathophysiology (Clauw, 2009; 
Maixner et al., 2016).  FM is characterized by widespread musculoskeletal pain without 
accompanying tissue inflammation or damage (Clauw, 2014). FM patients also have diffuse 
hyperalgesia (elevated pain responses to painful stimuli) and allodynia (perception of pain for 
normally non-painful stimuli). Additional markers of centralized pain are comorbid CNS-
mediated symptoms such as fatigue, insomnia, and mood disorders. Finally, FM patients are 
hypersensitive to a variety of non-noxious sensory stimuli (such as light, noise, and odors) 
(Petzke et al., 2003; Geisser et al., 2008; Wilbarger and Cook, 2011; López-Solà et al., 2014; 
Harte et al., 2016; Martenson et al., 2016), which suggests a more global dysfunction in sensory 
processing.  The widespread nature of the pain, lack of conclusive peripheral abnormalities, and 
accumulating neuroimaging evidence point to the CNS as the primary driver in the amplification 
and persistence of pain in FM. 
Central Nervous System Alterations in Fibromyalgia 
The CNS plays an active role in pain processing and can either enhance or diminish the 
perception of pain.  The perception of pain is a product of the activity in a diverse network of 
brain regions, including the somatosensory cortex (S1), insula, anterior cingulate cortex (ACC), 
prefrontal cortex, thalamus, hypothalamus, amygdala, hippocampus, cerebellum, periaqueductal 
gray (PAG) and other brainstem nuclei (Lee and Tracey, 2013). 
Studies of chronic pain patients using noninvasive techniques to study human brain 
function, such as functional magnetic resonance imaging (fMRI), proton magnetic resonance 
spectroscopy (1H-MRS), and positron emission tomography (PET), have confirmed alterations in 
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the functional, chemical and structural brain networks responsible for sensory processing.  These 
alterations fall into two broad categories: increased pro-nociceptive processing and/or decreased 
descending anti-nociceptive transmission, both of which may be driven by imbalances in 
excitatory and inhibitory neurotransmitters. 
In various chronic pain conditions, there is increased activity in “normal” pain processing 
regions, which may reflect the subjective magnitude or salience of the pain (Apkarian et al., 
2011).  Gracely and colleagues demonstrated that FM patients rated the intensity of an equal 
pressure stimulus as significantly more painful than controls.  Using fMRI, they also showed that 
FM patients had increased activation in a distributed network of pain processing regions, 
including S1, insula and ACC, during the application of this equal pressure stimulus compared to 
healthy controls (Gracely et al., 2002). Other studies have confirmed the leftward shift in the 
stimulus response function and increased activation in pro-nociceptive pain processing regions 
during painful stimuli in chronic pain patients relative to healthy volunteers (Cook et al., 2004; 
Giesecke et al., 2004; Gracely, 2004; Pujol et al., 2009; López-Solà et al., 2016).  
 One method of assessing the brain-based changes related to FM involves functional 
interactions between regions thought to be involved in pain.  Functional connectivity is defined 
as the statistical covariation between activities in different brain regions and has been used as a 
surrogate for network-based activity (for a review on functional connectivity methods and 
interpretations, see van den Heuvel and Pol, 2010).  The brain is organized into large-scale 
networks, wherein the neural activities of the component brain regions are highly correlated over 
time and spontaneously active even during the resting state. The most commonly reported 
networks include: sensorimotor network, visual network, salience network, fronto-parietal 
network, and the default mode network (DMN).  The DMN is thought to be involved in self-
	   4	  
referential processing and includes the posterior cingulate, precuneus, lateral parietal lobes and 
the medial prefrontal cortex.	  
FM patients, relative to healthy controls, also have increased functional connectivity 
between pro-nociceptive brain regions, specifically between the DMN and the insula (Napadow 
et al., 2010).  Further, the magnitude of this connectivity is positively correlated with clinical 
pain intensity (Napadow et al., 2010; Flodin et al., 2014).  Reductions in DMN – insula 
connectivity correlate with decreases in clinical pain intensity after a non-pharmacological 
treatment (Napadow et al., 2012).  FM patients also have increased functional connectivity 
between the DMN and secondary somatosensory cortex, ACC and insula, and M1 with 
supplementary motor areas (Cifre et al., 2012; Pujol et al., 2014).  More recently, our laboratory 
reported increases in resting state functional connectivity after an experimental pain task between 
the insula and ACC, and between the thalamus and precuneus/posterior cingulate cortex (key 
regions of the DMN).  These connectivity changes were positively correlated with increases in 
clinical pain intensity over the course of the scan (Ichesco et al., 2016). The functional and 
structural changes observed in FM may be common across other pain conditions.  In a large 
study, patients with chronic pelvic pain (a condition that shares the centralized pain phenotype) 
displayed increased gray matter volume in S1/M1 and increased functional connectivity between 
these regions and the insular cortex (Kutch et al., 2017).  These findings were confirmed in FM 
patients, but were absent in pain-free healthy controls.  
FM patients also have deficits in descending analgesia.  During a pressure pain paradigm, 
FM patients had decreased activation in anti-nociceptive brain regions, including the rostral ACC 
and brainstem (Jensen et al., 2009).  FM patients had decreased functional connectivity in 
descending pain inhibitory pathways during this pain task, specifically between the ACC, 
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amygdala, hippocampus and brainstem, and between the thalamus and orbitofrontal cortex 
(Jensen et al., 2012). The decreases in functional connectivity between anti-nociceptive 
structures (ACC, thalamus and insula to PAG) are also present during the resting state (Cifre et 
al., 2012; Pujol et al., 2014).  A recent meta-analysis found that FM patients have decreased gray 
matter volume in anti-nociceptive regions such as the ACC (Shi et al., 2016). In summary, FM 
patients have increases in activity, connectivity and gray matter volume in pro-nociceptive brain 
regions and decreases in activity, connectivity and gray matter volume in anti-nociceptive areas 
(summarized in Figure 1.1). 
 
Figure 1.1. Summary of Alterations in Pro- and Anti-Nociceptive Brain Activity.  FM patients have increased activation during 
experimental pain tasks in pro-nociceptive brain regions such as the insula, M1, S1, dorsal ACC and thalamus.  Patients also 
have increased functional connectivity at rest between pro-nociceptive brain regions and the DMN.  Moreover, FM patients have 
decreased descending analgesic activity in anti-nociceptive brain regions such as the rostral ACC and PAG.  Further there is 
evidence of decreased functional connectivity to these anti-nociceptive structures. FM, fibromyalgia; M1, primary Motor Cortex; 
S1, primary somatosensory cortex; ACC, anterior cingulate cortex; PFC, prefrontal cortex; DMN, default mode network; PAG, 
periaqueductal gray 
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The altered activation and connectivity patterns observed in FM may be due to 
imbalances in the excitatory and inhibitory neurotransmitters that play a role in pain perception.  
FM patients have increased cerebrospinal fluid levels of the pro-nociceptive neurotransmitters 
substance P, nerve growth factor and glutamate (Russell et al., 1994; Giovengo et al., 1999; 
Sarchielli et al., 2007), and decreased levels of the anti-nociceptive neurotransmitters serotonin, 
norepinephrine and dopamine (Russell et al., 1992).  1H-MRS is a non-invasive MRI technique 
that measures the relative concentration of brain metabolites in vivo.  Using this technique, our 
laboratory has shown that FM patients have decreased levels of γ-aminobutyric acid (GABA), 
the brain’s major inhibitory neurotransmitter, in the anterior insula and increased levels of 
glutamine + glutamate (Glx; the latter being the brain’s major excitatory neurotransmitter) in the 
posterior insula (Harris et al., 2009; Foerster et al., 2012).  These alterations in GABA and Glx 
were associated with increased experimental pain sensitivity. Other studies have found higher 
concentrations of Glx in the posterior cingulate, a key node of the DMN, of FM patients relative 
to healthy volunteers (Fayed et al., 2010).   
Numerous studies have found alterations in baseline opioidergic activity in FM (see 
Goldenberg et al., 2016 for a recent review).  Briefly, FM patients have reduced µ-opioid 
receptor availability (as measured with the PET radiotracer [11C]-carfentanil) in several pain 
processing regions, including the ACC, amygdala and nucleus accumbens, and this reduction 
was associated with clinical pain intensity (Harris et al., 2007).  These data can be interpreted in 
two ways that are not mutually exclusive: FM patients may have increased endogenous opioid 
levels or fewer opioid receptors.  Opioid analgesics do not effectively treat FM pain and low 
dose naltrexone, an opioid receptor antagonist, improves FM symptoms, which supports the 
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hypothesis that FM patients have excess endogenous opioid activity (Younger and Mackey, 
2009; Younger et al., 2013; Goldenberg et al., 2016).  
As briefly outlined, FM patients have alterations in the function, structure and 
neurochemistry of brain regions involved in pain processing.  Importantly, none of the brain 
regions or networks mentioned above is uniquely associated with the perception of pain.  They 
contribute to many other sensory, cognitive and emotional processes, which may explain the 
presence of a wide variety of symptoms in addition to the widespread pain seen in centralized 
pain states.  Since there is most likely not a ‘primary nociception cortex,’ it may be that 
coordinated activity within a network of regions modulates the perception of pain (Lee and 
Tracey, 2013).  As such, studying the brain as a complex network of interconnected regions 
might provide unique insights to the underlying pathophysiology of chronic centralized pain 
conditions. 
The Brain as a Complex Network: Introduction to Graph Theory 
Graph theory is a set of mathematical tools to examine the structure and function of 
networks. The organization, or topology, of a network is critical to its function because it 
influences the efficiency and content of information transfer (Bullmore and Sporns, 2012; Moon 
et al., 2015; 2017).  The brain is a network that shares an optimal pattern of organization with 
many other physical and biological systems (e.g., the Internet or social networks).  Many of these 
networks have a “small-world” organization, which strikes a balance between the need for 
segregated processing and rapid information integration (Sporns and Zwi, 2004).  
For an intuitive description of network concepts, consider an analogy: network structure 
and information flow can be thought of in terms of airport organization and travel.  The air 
transportation network is a collection of nodes (airports) and edges (flight routes between 
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airports).  Small regional airports, with few connections, represent peripheral nodes.  Large, 
highly trafficked airports are called hubs.  States could be considered modules, usually 
containing many regional airports and one large hub.  Hub nodes occupy a highly-connected and 
functionally-central role in the network.  They create short-cuts and long-distance connections, 
keeping the path length between airports in different modules short.  Hub airports are also highly 
interconnected to one another and this organizational structure, termed the “rich-club,” serves as 
a core backbone of the network and makes long-distance travel extremely efficient.   
In the case of the brain, nodes represent neurons and/or brain regions and edges are the 
structural or functional connections between nodes.  Hub brain regions, just like hub airports, 
facilitate communication and information integration across distinct modules (i.e. functional 
systems) of the brain.  A strong hub structure is an important characteristic of the small-world 
architecture of the brain, ensuring a short average path length and high global efficiency, while 
maintaining functional modularity (Sporns and Zwi, 2004).  Brain networks also have a rich-club 
organization, in which hubs are more likely to be connected to each other than to peripheral 
nodes (Colizza et al., 2006; Gorka Zamora-López, 2010; van den Heuvel and Sporns, 2011).  
The rich club forms a densely connected network core wherein hubs are thought to act in concert 
and link different functional systems in the brain (van den Heuvel and Sporns, 2011; van den 
Heuvel et al., 2012).   In the healthy human brain, the precuneus/posterior cingulate, ACC, and 
medial prefrontal cortex have been identified as multimodal functional hubs that participate in 
numerous functional networks (van den Heuvel and Sporns, 2013). Importantly, while hubs 
create efficiency, they also create network vulnerability wherein disruption of hub organization 
can have widespread consequences for information transfer.  
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Alterations in optimal network structure have been reported in chronic pain disorders 
(Balenzuela et al., 2010; Liu et al., 2012; Mansour et al., 2017).  Balenzuela and colleagues 
analyzed the community membership across the whole brain network and found that in healthy 
controls, the insula belonged to a community that included the sensorimotor cortices and 
cingulate gyrus.  However, in chronic pain patients, the insula was abnormally integrated into the 
auditory and visual networks (Balenzuela et al., 2010). A recent study including patients from 
three chronic pain conditions confirmed and extended these findings – in healthy controls, the 
insula was consistently a member of the sensorimotor community, while in patients the insula 
was more often a member of the DMN, subcortical, salience or attention networks (Mansour et 
al., 2017).   
Beyond pain conditions, work in other clinical populations has shown that hubs may be 
disproportionately affected in neurological disorders (Crossley et al., 2014; Stam, 2014). A 
recent meta-analysis of 26 diverse brain disorders found that gray matter alterations were more 
likely to be in hubs and rich club hubs in particular (Crossley et al., 2014).  These studies 
demonstrate that graph theory can be a useful tool to probe the underlying network architecture 
associated with chronic pain. However, how brain hub topology is altered in FM, and its 
relationship to underlying neurochemistry and patient self-reported clinical pain is largely 
unknown.  More broadly, it remains unknown how alterations in neurotransmitter levels (which 
are major factors influencing neural activity) in a clinical population may relate to changes in 
hub strength and rich club membership.  Characterizing hub topology in chronic pain could 
provide insight into the pathology of these disorders. 
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Treatments for Fibromyalgia 
Chronic pain conditions with a primarily nociceptive, inflammatory or neuropathic cause 
are generally well understood and effectively treated by health care providers (Arnold et al., 
2016).  However, conditions where the CNS is the primary driver in pain perception, such as 
FM, are often misunderstood and current treatments inadequate.  Centralized pain disorders are 
notoriously unresponsive to treatments that target the periphery and that work well for 
nociceptive pain (e.g. injections, surgery).  Moreover, oral analgesics that work well for 
peripherally driven pain, such as non-steroidal anti-inflammatory drugs and opioids, do not 
effectively treat FM pain and emerging evidence suggests that opioids may worsen hyperalgesia 
in these patients (Brummett et al., 2013; Clauw, 2014; Goldenberg et al., 2016).  Instead, most 
effective treatments target the neurotransmitter systems and brain networks involved in the 
perception of pain.   
Effective pharmacological therapies for FM include drugs that either raise levels of 
serotonin and norepinephrine (tricyclics such as amitriptyline, and serotonin norepinephrine 
reuptake inhibitors such as duloxetine and milnacipran), or those that decrease glutamate 
(gabapentinoids such as pregabalin; see Schmidt-Wilcke and Clauw, 2010; Clauw, 2014 for 
reviews on drug therapy and their neurobiological mechanisms in FM).  In a recent randomized, 
placebo-controlled trial of milnacipran in FM, our laboratory found that FM patients who had the 
greatest reduction in clinical pain after treatment had altered connectivity at baseline between 
pro- and anti-nociceptive regions (Schmidt-Wilcke et al., 2014).  This finding is supported by 
another trial in which milnacipran was found to increase activity in anti-nociceptive brain 
regions during an evoked pain task (Jensen et al., 2014).  In another placebo-controlled trial, 
pregabalin reduced Glx in the posterior insula and decreased experimental pressure pain 
	   11	  
sensitivity in FM (Harris et al., 2013).  After treatment these patients also had decreased 
connectivity between the insula and DMN, and this change in connectivity was associated with a 
reduction in clinical pain.   
Only a subset of chronic pain patients respond to current pharmacological therapies 
(Häuser et al., 2014), hence there is a critical need for new treatments that target the CNS 
alterations seen in these individuals. Noninvasive brain stimulation has emerged as an attractive 
treatment, given its ability to target specific cortical regions with relatively few side effects.  
Transcranial direct current stimulation (tDCS) of M1 significantly increases experimental pain 
thresholds in healthy controls (Reidler et al., 2012) and causes lasting clinical pain reduction in 
FM (Fregni et al., 2006; Valle et al., 2009; Fagerlund et al., 2015).  M1 tDCS may also improve 
other symptoms in FM such as sleep disturbances and depression (Roizenblatt et al., 2007; Khedr 
et al., 2017).  Other stimulation sites, such as the dorsolateral prefrontal cortex, have been 
explored in FM, but in a comparison trial, M1 stimulation produced the most robust analgesic 
response (Valle et al., 2009).  Although these studies are encouraging, the effect sizes are small 
and a large review concluded that there is only low-quality evidence for M1 tDCS as an effective 
treatment for chronic pain (O'Connell et al., 2014).  The mixed results may be due in part to 
variation in stimulation parameters, the duration of treatment and inclusion of many chronic pain 
conditions.  A more recent review of high quality tDCS studies found probable efficacy for pain 
reduction in FM (Lefaucheur et al., 2017). Some of the variation in analgesic efficacy may also 
be explained by the underlying neurobiology augmenting the perception of pain in each 
condition and, indeed, each patient.  By combining an understanding of the CNS alteration 
driving pain perception with the knowledge of analgesic mechanisms of action of treatments, 
personalized treatment for chronic pain may become a reality. 
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Analgesic Mechanisms of Motor Cortex tDCS 
During a typical tDCS session, the stimulating electrode (anode) is placed over M1 and a 
reference electrode (cathode) is placed over the contralateral supraorbital area.  A weak electrical 
current (between 1 – 2 mA) is applied to the scalp and passed between the electrodes for 
durations of 5 to 30 minutes. tDCS effects are often examined in comparison to a sham (placebo) 
procedure.  During the sham condition, electrodes are applied and positioned exactly as in the 
active condition but the current is applied for only 30 seconds and then discontinued.  The 
sensations on the scalp during an active session can only be felt during the early phase of 
treatment, hence the sham condition is an effective placebo (DaSilva et al., 2011).  
The electrical current applied in tDCS modifies resting membrane potential, thereby 
modulating the excitability and firing rates of cortical neurons.  As a general rule, anodal 
stimulation increases cortical excitability by depolarizing neurons, an effect that persists after the 
stimulation period depending on the intensity and duration of stimulation (Stagg and Nitsche, 
2011).  Conversely, cathodal stimulation has an inhibitory effect by hyperpolarizing neurons 
(Rosen et al., 2009).  Unlike other invasive and non-invasive brain stimulation methods (e.g., 
invasive motor cortex stimulation and transcranial magnetic stimulation), tDCS does not 
generate action potentials (Zaghi et al., 2010).  Although this general observation provides some 
guidance, it is likely too simplistic.  tDCS may also reduce membrane resistance (or increase 
conductance), and the size of this effect depends on the baseline state of the neuron.  Moreover, 
tDCS effects depend on the relationship between the stimulated area and structurally connected 
regions, and any pathological alterations of neurotransmitter systems (Lefaucheur et al., 2017). 
Finally, stimulation intensity, duration, number of repetitions and electrode size, shape and 
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placement can also impact the strength, diffusion and excitability of the electrical current 
(Lefaucheur et al., 2017).  
Axons are more susceptible to the electrical current applied during brain stimulation 
compared to cell bodies, so mechanisms should be examined in terms of the impact on networks 
rather than on any individual brain region (Lefaucheur, 2016). Computational models of M1 
tDCS depict current flow reaching areas under the stimulating electrode in addition to more 
distal cortical and subcortical regions (DaSilva et al., 2012).  These models have been borne out 
by in vivo studies of tDCS effects; anodal M1 tDCS increases activity and connectivity in the 
underlying M1 cortex (Kwon et al., 2008; Polanía et al., 2012a; Sehm et al., 2013) and has a 
sustained impact on the neural activity of distant cortical and subcortical regions (Lang et al., 
2005). Using graph-theoretical techniques, Polania and colleagues examined network 
connectivity before and immediately after anodal M1 tDCS in healthy participants.  They found 
that M1 tDCS (compared to sham) increased the number of functional connections in the 
posterior cingulate and the dorsolateral prefrontal cortex (Polanía et al., 2011).  Specifically, 
there was increased connectivity between the posterior cingulate and other DMN regions and 
between the dorsolateral prefrontal cortex and the anterior insula.  They also found decreased 
long-distance connectivity in S1, and a concomitant increase in short-range connections between 
S1 and M1. Sehm and colleagues found that M1 tDCS altered connectivity in prefrontal, parietal 
and cerebellar regions during stimulation and the effects persisted for at least 15 minutes in 
healthy volunteers (Sehm et al., 2012).   
There has not been substantial research on the neurobiology of M1 tDCS analgesia. 
However, studies from invasive motor cortex stimulation, other types of non-invasive brain 
stimulation and animal models can provide insight into potential mechanisms of action. 
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Importantly, the hypotheses outlined below are not mutually exclusive and could occur 
synergistically to produce analgesia. 
Thalamocortical Hypothesis 
The ventral lateral and ventral posterior lateral thalamic nuclei have direct connections to 
the motor and somatosensory cortices, and are involved in motor functions and the sensory-
discriminative aspect of pain (Zhang et al., 2010).  One influential hypothesis states that M1 
stimulation causes analgesia by decreasing thalamic hyperactivity (Tsubokawa et al., 1991; 
1993; Nguyen et al., 2011). In studies of healthy rats and rats with neuropathic pain, researchers 
performed a paw pressure noxious stimulus test and found that following invasive M1 
stimulation, the withdrawal threshold was increased compared to sham (meaning that it takes 
more pressure to induce the withdrawal response, which is interpreted as anti-nociception).  
Furthermore, neuronal firing rates in the ventral posterior lateral thalamus decreased during M1 
stimulation, while the firing rate of neurons in the PAG increased (Pagano et al., 2011; 2012). 
Garcia-Larrea and colleagues demonstrated that invasive M1 stimulation in patients with 
neuropathic pain caused an increase in cerebral blood flow in the ventral lateral thalamus, ACC, 
anterior insula and upper brainstem (García-Larrea et al., 1999). Together, these data suggest that 
M1 stimulation may activate inhibitory corticothalamic fibers, which results in thalamic 
inhibition (Zaghi et al., 2009).   
tDCS also increases pain and sensory thresholds in healthy volunteers and causes lasting 
pain relief in chronic pain conditions (Vaseghi et al., 2014), perhaps due to the modulation of 
thalamic sensory pathways.  In a study of healthy volunteers measuring regional cerebral blood 
flow with PET, researchers found increased blood flow in M1, S1 and the ventral posterior 
lateral thalamus immediately after anodal M1 tDCS compared to sham, which is similar to the 
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findings using invasive M1 stimulation (Lang et al., 2005).  In another study using healthy 
controls, M1 tDCS increased functional connectivity between M1 and thalamus relative to the 
sham condition (Polanía et al., 2012b).  It is important to note that these studies were done during 
or immediately after tDCS and that thalamic activity may either increase or decrease depending 
on the timing of measurement (Peyron et al., 2007).  Our laboratory has shown that after five 
days of M1 tDCS in FM patients there was trend towards decreased Glx in the bilateral thalami 
compared to sham, although this did not meet statistical significance (Foerster et al., 2014). This 
was a small study that needs to be replicated, but it suggests that M1 tDCS may also act via 
corticothalamic pathways in chronic centralized pain. 
Endogenous Opioid Hypothesis 
Another hypothesis states that M1 stimulation may cause analgesia via activation of the 
endogenous opioid system, a major pain modulatory system. In a PET study of cerebral blood 
flow in neuropathic pain patients there was an increase in blood flow in the ACC, orbitofrontal 
cortex, putamen, and PAG that persisted 75 minutes after the cessation of invasive M1 
stimulation (Peyron et al., 2007).  Most of these changes in blood flow were associated with 
analgesia. Additionally, the authors found a significant increase in functional connectivity 
between the ACC and PAG, leading to the hypothesis that M1 stimulation activates descending 
anti-nociceptive systems.  The ACC and PAG contain a high density of opioid receptors, and are 
important players in opioid analgesia (Jones et al., 1991; Petrovic, 2002).  Relative to a 
preoperative PET scan, Maarrawi and colleagues found a reduction in binding potential with the 
non-selective opioid antagonist [11C]diprenorphine in the ACC and PAG after seven months of 
invasive M1 stimulation for the treatment of neuropathic pain (Maarrawi et al., 2007).  A later 
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study showed that the density of opioid receptors in these regions - in addition to the thalamus, 
insula and orbitofrontal cortex - predicted postoperative pain relief (Maarrawi et al., 2013).  
Naloxone, an opioid receptor antagonist, blocks the analgesic effects of M1 tDCS in 
healthy controls (de Andrade et al., 2011).  Research combining PET and tDCS confirms that 
tDCS may also act on the endogenous opioid system.  In a neuropathic pain patient, M1 tDCS 
(compared to sham) caused a release of endogenous opioids in the nucleus accumbens, ACC, 
insula and thalamus (DosSantos et al., 2012).  A later study confirmed these results, in addition 
to increased release in the PAG, in healthy controls during M1 tDCS (DosSantos et al., 2014).  
Since the sham tDCS condition also caused endogenous opioid release in many of the same 
regions, placebo effects cannot be ruled out. 
As stated above, chronic centralized pain patients have alterations in the endogenous 
opioid system (either increased levels of circulating endogenous opioids or fewer opioid 
receptors).  It is unclear if the findings from healthy volunteers and neuropathic pain patients 
would extend into chronic pain conditions.  It is also unknown how tDCS alters endogenous 
opioid tone or receptor density after repeated tDCS sessions, as an FM patient would be treated 
in a clinical setting.  This is beyond the scope of the current dissertation, but should be examined 
in future studies.   
Neuronal Plasticity Hypothesis 
The analgesic effects of tDCS can last well beyond the end of a treatment session and 
outcomes are generally improved with repeated sessions (Monte-Silva et al., 2013).  Antagonists 
at the glutamate N-methyl-D-aspartate (NMDA) receptor, a key regulator of synaptic plasticity, 
can abolish the analgesic effects of M1 stimulation (Liebetanz et al., 2002; Ciampi de Andrade et 
al., 2014).  Anodal tDCS to the parietal cortex increased Glx in the same region (Clark et al., 
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2011).  After repetitive S1 transcranial magnetic stimulation in chronic visceral pain patients, 
there was a significant increase in S1 Glx and this change was associated with a reduction in 
clinical pain (Fregni et al., 2011).  Anodal tDCS can also reduce GABA near the stimulating 
electrode, which may impact glutamatergic plasticity as well (Stagg et al., 2009; Lefaucheur et 
al., 2017).  tDCS also alters functional connectivity below the stimulating electrode as well as 
distant cortical regions (Polanía et al., 2011; Sehm et al., 2012; Polanía et al., 2012a; 2012b; 
Sehm et al., 2013).  The baseline activity of the neural network can determine the effect of tDCS 
and ‘priming’ the network by having participants perform a task during stimulation can 
potentiate behavioral effects (Lefaucheur et al., 2017).  For example, when M1 tDCS is applied 
during a motor learning task, performance is better and improvements are longer lasting 
compared to tDCS alone (Reis et al., 2009; Reis and Fritsch, 2011; Zimerman et al., 2013).  This 
principle also applies to other cognitive domains and stimulation sites (Cohen Kadosh et al., 
2010; Meinzer et al., 2014).  All together, these facts strongly suggest that the long term changes 
seen after noninvasive brain stimulation involve neural plasticity, possibly via long-term 
potentiation or long-term depression-like mechanisms (Monte-Silva et al., 2013; DosSantos et 
al., 2016). 
Placebo Hypothesis 
The placebo response is attributable to the psychobiological effects of the treatment 
process itself, rather than any active component of a drug or non-drug treatment (Wager and 
Fields, 2013).  Neuroimaging studies have revealed an overlap between brain networks involved 
in pain processing and those implicated in the placebo response (Tracey, 2010; Meissner et al., 
2011).  Placebo analgesia is associated with activity in descending anti-nociceptive systems, 
including the release of endogenous opioids, and the inhibition of ascending pro-nociceptive 
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activity (Zubieta and Stohler, 2009; Wager and Fields, 2013).  Placebo responses are clearly 
present in tDCS and may account for a portion of the analgesic effect.  One study found that 
sham tDCS causes the release of endogenous opioids in the PAG, precuneus and thalamus 
(DosSantos et al., 2014).  These findings led to the suggestion that the placebo response to tDCS 
could be leveraged to provide a larger analgesic response when real tDCS is subsequently 
applied.  Active tDCS may be reinforcing brain networks that are activated by the expectation of 
pain relief (similar to the enhanced effects when tDCS is combined with a motor or cognitive 
task outlined above).  This idea can be summarized as “functional targeting” and may shed light 
on how tDCS targets specific networks when the electrical current itself is rather widespread and 
diffuse (Schambra et al., 2014). 
To summarize, tDCS is an emerging technology that may hold promise for relieving pain 
symptoms through network-level changes.	   It is clear that tDCS can alter functional connectivity 
and the neurochemistry of regions underneath and distant to the stimulating electrode.  
Importantly, most of the studies outlined above in healthy controls or neuropathic pain patients 
examined the neurobiological effects of M1 stimulation during or immediately after stimulation 
had ended. It is unclear if these results translate to chronic centralized pain conditions. There 
have not been any studies measuring changes in functional connectivity after repetitive 
treatments of tDCS in chronic pain patients, as they would be treated in clinical practice. 
Aims and Hypotheses of this Dissertation 
The goals of this dissertation are to (1) elucidate changes in brain network topology, 
specifically within regions fundamental to information flow and integration (i.e. hubs), in a 
common chronic centralized pain condition and (2) determine how a non-pharmacological 
treatment may alter network connectivity to cause analgesia.  The overarching hypothesis is that 
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there is a reorganization of hub regions in chronic pain, which may contribute to amplifying or 
sustaining the perception of pain independently of peripheral nociceptive input.   Further, we 
hypothesize that disordered hub regions are prospective targets for non-invasive brain 
stimulation therapy and that tDCS cause analgesia by disrupting functional connectivity between 
regions involved in pain perception.   
In Chapter 2, we apply a brain network based approach to examine hub topology in 40 
FM patients compared to 27 healthy volunteers using graph theoretical techniques.  Given the 
widespread nature of pain and hypersensitivity to other sensory modalities in FM, we 
hypothesize that the FM brain network will have altered hub organization and rich-club 
membership of pain and sensory processing regions (such as the insula and S1). We further 
hypothesize that these differences will be related to neurochemistry and clinical pain intensity. 
In Chapter 3, we examine resting state functional connectivity in 12 FM patients at 
baseline, after five days of sham tDCS, and after five days of anodal M1 tDCS treatment.  We 
sought to answer three questions: (1) Can functional connectivity at baseline predict subsequent 
analgesia after M1 tDCS? (2) How does M1 tDCS (compared to sham) alter functional 
connectivity? and (3) Do changes in connectivity relate to treatment response?  Previous studies 
have shown that structural connectivity between M1 and the thalamus may be important for 
analgesia after a similar noninvasive brain stimulation technique (Goto et al., 2008; Ohn et al., 
2012). Therefore, we hypothesize that FM patients with stronger M1-thalamus connectivity at 
baseline will predict a better clinical response.  Additionally, since we found a trend towards 
decreased Glx in the thalamus after M1 tDCS in the same patients studied here (Foerster et al., 
2014), we expect that M1 tDCS will decrease functional connectivity between the thalamus and 
brain regions involved in pain perception and that these changes will relate to analgesia. 
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In total, this research may offer new insight into the pathophysiology of chronic 
centralized pain conditions, may be a clinically useful diagnostic marker of chronic pain, and 
may contribute to the understanding of how noninvasive brain stimulation treatments cause 
analgesia. This knowledge could lead to more informed stimulation sites and personalized 
treatment based on the brain network connectivity in an individual patient.  Finally, an 
understanding of how alterations in the excitatory-inhibitory balance in one brain region might 
affect information transfer in the whole brain network would be of foundational neuroscientific 
importance.  
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Chapter 2 : Functional and Neurochemical Disruptions of Brain Hub 
Topology in Chronic Pain 
Introduction 
The perception of acute pain is a product of neural activity in a widely distributed brain 
network, typically following noxious insult.  In chronic pain conditions, however, altered 
processing within this network can create, amplify, or sustain the perception of pain independent 
of noxious stimulation (Sluka and Clauw, 2016). Therefore, a network approach may offer 
critical and unique insights into the pathogenesis of chronic pain conditions (Farmer et al., 2012; 
Kucyi and Davis, 2015).   
Brain networks can be modeled using graph theoretical tools as a set of functional 
interactions made up of nodes (neurons and/or brain regions) and edges (structural or functional 
connections between nodes). The organization, or topology, of a network is critical to its 
function because it influences the efficiency and content of information transfer among nodes 
(Moon et al., 2015; 2017). The human brain network has been described as “small-world,” a 
topology that strikes a balance between segregated processing and rapid information integration 
(Sporns and Zwi, 2004).   
A critical component of small-world architecture is a robust hub structure, wherein hub 
nodes facilitate efficient information integration across the brain by occupying a highly-
connected and functionally-central role in the network (van den Heuvel and Sporns, 2013).  
Brain networks also have a higher order level of organization called “rich-clubs,” in which hubs 
are more likely to be connected to each other than to nodes with fewer connections (Colizza et 
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al., 2006; Gorka Zamora-López, 2010; van den Heuvel and Sporns, 2011).  This rich club forms 
a densely connected network core wherein hubs are thought to act in concert and link different 
functional systems in the brain (van den Heuvel and Sporns, 2011; van den Heuvel et al., 2012).    
Importantly, while hubs create efficiency, they also create network vulnerability wherein 
disruption of hub organization can have widespread consequences for information transfer. Work 
in clinical populations has shown that hubs may be disproportionately affected in neurological 
disorders (Crossley et al., 2014; Stam, 2014). A recent meta-analysis of 26 diverse brain 
disorders found that gray matter alterations were more likely to be in hubs and rich club hubs in 
particular (Crossley et al., 2014).  Characterizing hub topology in clinical conditions may 
therefore provide insight into the pathology of these disorders. Alterations in optimal network 
structure have been reported in chronic pain disorders (Balenzuela et al., 2010; Liu et al., 2012; 
Mansour et al., 2017).  However, how brain hub topology is altered in chronic pain, and its 
relationship to underlying neurochemistry and patient self-reported clinical pain is largely 
unknown.  More broadly, it remains unknown how alterations in neurotransmitter levels in a 
clinical population may relate to changes in hub strength and rich club membership.   
Here we used a graph theoretical approach in conjunction with resting state functional 
MRI (fMRI) and proton magnetic resonance spectroscopy (1H-MRS) to examine hub topology 
and brain neurochemistry in fibromyalgia (FM), a common chronic pain condition with 
significant central nervous system contributions (Clauw, 2014).  In addition to widespread pain 
and hyperalgesia without clear evidence of ongoing peripheral inflammation or damage, FM 
patients display hyper-sensitivity to a variety of non-noxious sensory stimuli (Geisser et al., 
2008; Harte et al., 2016; López-Solà et al., 2014; Martenson et al., 2016; Petzke et al., 2003; 
Wilbarger and Cook, 2011), as well as other brain-related symptoms such as disturbances in 
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energy, sleep, memory and mood.   FM patients consistently display evidence of augmented pain 
and sensory processing on fMRI (Gracely et al., 2002; López-Solà et al., 2016), and altered 
functional connectivity in pro- and anti-nociceptive regions (Ichesco et al., 2014; 2016; Jensen et 
al., 2009; Napadow et al., 2010).  Moreover, FM patients have altered levels of excitatory and 
inhibitory neurotransmitters within the insula and other sensory processing regions (Foerster et 
al., 2012; Harris et al., 2009).   We hypothesized that the FM brain network would have altered 
hub organization and rich-club membership of pain-associated regions (such as the insula). We 
further hypothesized that these differences would be related to neurochemistry and clinical pain 
intensity. 
Materials and Methods 
Participants. Data from 40 female FM patients and 27 age- and sex-matched HCs were pooled 
from previous fMRI studies and analyzed retrospectively using a graph-theoretical approach. The 
data from 31 FM and 27 HCs were previously published in manuscripts focusing on functional 
connectivity, 1H-MRS, and treatment outcomes (Harris et al., 2009; 2013; Harte et al., 2016; 
Ichesco et al., 2014; Napadow et al., 2010; 2012; Puiu et al., 2016; Schmidt-Wilcke et al., 2014). 
Data from the remaining nine FM patients has not been published. The University of Michigan 
Institutional Review Board approved the studies and written informed consent was obtained from 
all participants in accordance with the Declaration of Helsinki. The major inclusion criteria for 
FM patients were: meeting the American College of Rheumatology (ACR) 1990 criteria for FM 
and at least 6 months of self-reported chronic widespread pain, a score of ≥ 40 mm on a 100 mm 
pain Visual Analog Scale (VAS) at the time of consenting. Both FM and HCs were 18-75 years 
of age, female, right-handed, and capable of giving written informed consent. Major exclusion 
criteria for both groups were
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urine drug screen or history of drug or alcohol abuse within the past two years, body mass index 
greater than 36, severe psychiatric illness, concurrent autoimmune or inflammatory disease that 
causes pain, or systemic malignancy or infection such as HIV or hepatitis. An additional 
exclusion criterion for HCs was meeting the ACR 1990 criteria for FM. 
Data Acquisition and Preprocessing. Self-reported clinical pain intensity in FM patients was 
assessed immediately before fMRI using a VAS, with 0 being “no pain” and 10 being the “worst 
pain imaginable”. Depression in FM patients was assessed on the day of the scan; 18 patients 
received the Hospital Anxiety and Depression scale (HADS) (Zigmond and Snaith, 1983), and 
12 patients received the Center for Epidemiological Studies-Depression Scale (CESD-D) 
(Radloff, 1977). Depression scores were converted to Z-scores in order to combine measures. 
Each participant completed a resting state fMRI scan and 1H-MRS sequence. Scanning was 
performed for all subjects on a 3.0 T General Electric (Milwaukee, WI) system with an eight-
channel head coil. The MRI scanner at the University of Michigan was upgraded to a new 3.0 T 
GE system with identical scanning parameters during one of the studies reported on here, so data 
from 3 FM participants was acquired on the new scanner. Group differences in graph theoretical 
measures did not change when excluding these participants (data not shown).  
Each participant completed a 6-minute resting state fMRI scan as described previously 
(Harris et al., 2013; Napadow et al., 2010; 2012). Data was collected using a spiral in-out 
gradient echo T2*-weighted blood oxygenation-level dependent pulse sequence with the 
following parameters: TR 2000ms/TE 30ms, 180 volumes, 43 AC-PC aligned slices, voxel size 
3.13 x 3.13 x 4.0 mm.  The first 6 volumes were discarded in order to avoid equilibration effects. 
A high-resolution structural image was collected for registration purposes (spoiled gradient echo 
pulse sequence: TR 14/TE 5.5/TI 300ms, 20° flip angle, 124 contiguous axial slices, voxel size 1 
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x 1 x 1.5mm). Cardiac and respiratory data were collected simultaneously using an infrared pulse 
oximeter (GE) attached to the right middle finger and a respiration belt placed around the 
participant’s ribcage. 
All data were checked for artifacts and motion greater than 2mm or 1° rotation in any 
direction. No participants were excluded for these reasons. Resting state data were preprocessed 
using FSL (http://www.fmrib.ox.ac.uk/fsl) and SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/software) running on MATLAB R2014a 
(http://www.mathworks.co.uk/products/matlab/). Physiological correction was done using the 
RETROICOR (Glover et al., 2000) algorithm in FSL.  All other preprocessing steps were done 
in SPM8 and included slicetiming, motion correction, co-registration of the structural and 
functional images, normalization to Montreal Neurological Institute (MNI) space and smoothing 
with an 8mm FWHM Gaussian Kernel. Preprocessed data were entered into the Conn Toolbox 
(Whitfield-Gabrieli and Nieto-Castanon, 2012), and a nuisance regression using the CompCor 
method (Behzadi et al., 2007) was performed with six subject-specific realignment parameters, 
the signal from white matter and CSF, and their first order derivatives included as confounds. 
Finally, a temporal filter of 0.008 – 0.09 Hz was applied to focus on low-frequency fluctuations 
(Fox et al., 2005). 
During 1H-MRS, the spectroscopic voxel was placed in the right posterior insula as 
described previously (Figure A.1A; Harris et al., 2008; 2009). Single-voxel point resolved 
spectroscopy spectra were acquired while participants were at rest with the following parameters: 
TR 3000ms/TE 30ms, 90-degree flip angle, number of excitations 8, number of averages 128, 
with a voxel size of 2 x 2 x 3 cm.  Shimming was optimized using auto-prescan and the 
CHEmical Shift Selective (CHESS) water suppression routine was used.  Spectra were analyzed 
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offline with LCModel (Stephan Provencher, Oakville, Ontario, Canada) (Provencher, 1993). 
Raw spectra were fit with a linear combination of pure metabolite spectra using LCModel (the 
basis set, which was simulated by Stephan Provencher of LCModel, included the following 
metabolites: Ala, Asp, Cr, PCr, GABA, Glc, Gln, Glu, GPC, PCh, Ins, Lac, NAA, NAAG, 
Scyllo, Tau).  See Figure A.1B for a representative spectrum. Glutamate + glutamine (Glx) 
values were calculated as concentrations rescaled using the water peak. Concentrations were 
corrected for CSF in each participant using Voxel Based Morphometry (VBM) within SPM8 as 
previously described (Harris et al., 2009).  To rule out the possibility of tissue volume biases in 
the 1H-MRS results, we analyzed the segmented gray/white matter and CSF content of the 
spectroscopic voxel and found that it was not significantly different between groups (Tables A.1 
and A.2). Spectra were excluded if the Cramer-Rao bounds exceeded 20% or if the FWHM was 
greater than 0.12. One FM participant with poor quality spectra was excluded from analysis.  
Graph theoretical analyses. The analysis flow is depicted in Figure 2.1. We defined the brain 
network using a set of 264 non-overlapping nodes based on resting state and task functional 
connectivity meta-analyses (Cohen et al., 2008; Jonathan D Power, 2011). This set of nodes has 
been shown to produce reliable network topologies (Cole et al., 2013; Dosenbach et al., 2007; 
Jonathan D Power, 2011; Spreng et al., 2013; Vatansever et al., 2015). The 264 nodes were 
entered into the Conn Toolbox as 10 mm diameter spheres (Jonathan D Power, 2011). We 
created Fisher z-transformed bivariate correlation (Pearson’s r) matrices (264 x 264) for each 
participant. Matrices were thresholded, over a range of relative thresholds (5 - 40% density, in 
steps of 5%), to create binary undirected graphs.  We calculated the following graph theoretical 
measures to assess global network properties: global efficiency, Louvain modularity Q score, 
clustering coefficient, characteristic path length and the rich club coefficient.  We also calculated 
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the nodal measures of degree, betweenness centrality, participation coefficient and eigenvector 
centrality. See (Rubinov and Sporns, 2010) or (Fornito et al., 2016) for a detailed description and 
mathematical formulations of these measures. All graph theoretical measures were calculated 
using the Brain Connectivity Toolbox (Rubinov and Sporns, 2010). To reduce the number of 
comparisons, for each metric and each node, we averaged across thresholds as previously 
published (Achard et al., 2012; Lynall et al., 2010). 
 
	  
Figure 2.1. Summary of Graph Theoretical Methods. Resting state fMRI data was collected for 40 FM patients and 27 HC.  264 
nodes were defined using the Power atlas (Jonathan D Power, 2011) which reliably segregate into large scale resting state 
networks. Pairwise (Fisher Z-transformed Pearson) correlation matrices were created for each participant, which were 
thresholded and binarized across a range of network densities. Graph theoretical measures were calculated and between-group 
differences were assessed using non-parametric permutation testing.  Post-hoc correlations between hub measures and clinical 
pain and glutamate were also performed.  
 
Hub Disruption Index.  The hub disruption index (κ) was calculated as previously described 
(Achard et al., 2012). Briefly, for each graph theory hub measure analyzed here (degree, 
betweenness, participation coefficient), we plotted the mean value of each node in the HC group 
versus the difference between an individual participant and the HC group for each corresponding 
node.  The κ is defined as the slope of a line fitted to these data. Between group differences in κ 
were examined using non-parametric permutation testing (Achard et al., 2012; Fornito et al., 
2016; Nichols and Holmes, 2002) under the null hypothesis that FM and HCs do not differ with 
respect to hub disruption. We randomly reassigned participants to one of two groups and 
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calculated a two-sample t-statistic. We repeated this procedure 10,000 times to form a 
randomized null distribution for each metric. We rejected the null hypothesis if the actual t-
statistic was greater than or equal to the 95th percentile of the null distribution. Significance was 
set at p < 0.05. 
Identification of Hubs. We assigned hub status to a node if the degree or betweenness centrality 
was greater than one standard deviation above the group mean (Sporns et al., 2007; van den 
Heuvel and Sporns, 2011). We further distinguished between provincial hubs (hubs that have 
connections mainly within one module) and connector hubs (hubs that have connections between 
many modules).  Hubs with a participation coefficient less than 0.5 were classified as provincial 
hubs, and hubs with a participation coefficient greater than 0.5 were defined as connector hubs 
(van den Heuvel and Sporns, 2011). Analyses of between group differences on nodal measures 
were restricted to hub regions. As outlined above, we performed non-parametric permutation 
testing on hub degree, betweenness centrality and participation coefficient to identify the specific 
hub differences between FM and HCs. Significance was set at p < 0.05.   
Rich Club Organization. We assessed rich-club organization in the average FM and HC brain 
networks by computing the rich-club coefficients ϕ (k) over a range of degree (k), as previously 
described (van den Heuvel and Sporns, 2011). Briefly, the degree of each node was calculated 
for the FM and HC networks and all nodes that had a degree ≤ k were ignored.  For the 
remaining nodes in the network, we calculated the rich-club coefficient ϕ (k) as the number of 
connections between the remaining nodes divided by the total number of possible connections.  
Random networks can also have an increasing function of ϕ (k) by chance alone; hence the ϕ (k) 
is typically normalized by a set of random networks.  We created 1000 random networks with 
similar degree distribution and density, and for each level of k, calculated the average rich-club 
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coefficient ϕ random.  We determined statistical significance of ϕ (k) at each level of k with 
permutation testing (Fornito et al., 2016; van den Heuvel and Sporns, 2011). Using the random 
networks created above, we obtained a null distribution of ϕ random (k) values. P-values were 
estimated as the proportion of ϕ random (k) that exceeded the observed ϕ (k) for FM and HC 
separately.  This was repeated over all levels of k and a Bonferroni correction (0.05/28) was 
applied so that p < 0.001 was deemed significant at 5% density.  The range of k in which ϕ (k) is 
significantly different from ϕ random (k), and where the ϕ norm (k) is greater than one, is the rich-
club regime. Differences between FM and HC in ϕ (k) at each level of k were tested in SPSS 24 
(Armonk, New York) using independent samples t-tests. To assess how rich club membership 
varied with clinical pain, we separated the FM group into age-matched tertiles (high n=12, 
medium n=16, low n=12) based on the VAS clinical pain rating. Differences in ϕ (k) between the 
tertiles were examined using a 1-way analysis of variance (ANOVA).  A Bonferroni correction 
was applied (0.05/28) and significance set at p < 0.001.  For visualization purposes, rich club 
nodes were displayed at k = 22, the highest level of k that was significantly different from 
random networks for the FM and HC groups, and also corresponded to nodes with a degree 
greater than one standard deviation above the group mean.   
Examining the relationship between hub status, clinical pain and Glx.  For correlations 
between hub measures and clinical pain and Glx, we performed Pearson correlations in SPSS. To 
test for differences in clinical variables and Glx between the FM tertiles, we performed 1-way 
ANOVAs in SPSS. All analyses controlled for age and significance was set at p < 0.05.  To test 
the hypothesis that higher levels of posterior insular Glx influence clinical pain indirectly 
through greater eigenvector centrality in the insula, we conducted mediation analyses using 
MPLUS v. 8.  Posterior insula Glx was used as the independent variable, and clinical pain on the 
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VAS was used as the dependent variable.  Eigenvector centrality values from two nodes 
overlapping the 1H-MRS voxel for the posterior insula (nodes 43 and 67) were standardized and 
averaged, and this value was used as the mediating variable.  Indirect effects were evaluated by 
constructing 95% bias-corrected bootstrapped confidence intervals using 20,000 resamples.  All 
models controlled for participant age.   
Visualization. The visualization of 264 nodes on a brain surface was created in Caret (Dickson 
et al., 2001; Van Essen et al., 2005).  All other brain surfaces were created using BrainNet 
viewer (Xia et al., 2013). 
Results 
Clinical Characteristics 
There was no significant difference in age between FM and HC participants (mean ± SD HC: 
36.2 ± 12.4, FM: 39.0 ± 11.0, t = 0.97, p = 0.34). Other patient characteristics and a list of 
current medications in the FM patients are listed in Tables A.3 and A.4, respectively. 
Fibromyalgia and Control Participants had Similar Global Network Properties 
Our initial aim was to characterize the global brain network properties of FM patients and 
controls. At every density of functional connections tested (5 - 40%), FM and HC networks had 
small-world organization, defined as high clustering (local connectivity) and a low average path 
length between nodes.  As these measures did not differ significantly between groups, we 
averaged all graph theory metrics across densities to reduce the number of comparisons when 
performing permutation testing to assess group differences (Achard et al., 2012; Lynall et al., 
2010).  There were no significant differences between groups in the clustering coefficient, 
average path length, modularity or global efficiency of the reconstructed brain network (all p > 
0.4, Table A.5).  
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Differences in Hub Status Between Fibromyalgia Patients and Controls  
The hub status of a node can be assessed by measuring the number of connections a node has 
(degree), the number of shortest paths in a network that pass through the given node 
(betweenness centrality), or the amount of connectivity to diverse functional systems 
(participation coefficient) (Sporns et al., 2007). For degree, betweenness centrality, and 
participation coefficient, we calculated the hub disruption index (κ) (Achard et al., 2012) to 
investigate brain regions with increased or decreased hub status in FM. A negative κ value 
indicates that hub nodes in HC are reduced in FM, and non-hubs in HC are classified as hubs in 
FM.  The κ was significantly more negative in the FM group for degree (κD mean ± SD, HC: 
0.00 ± 0.24, FM: -0.16 ± 0.28, t = 2.50, p = 0.015, Figure 2.2A), betweenness centrality (κBC 
mean ± SD, HC: 0.00 ± 0.27, FM: -0.16 ± 0.21, t = 2.58, p = 0.012, Figure 2.2B) and 
participation coefficient (κPC mean ± SD, HC: 0.00 ± 0.38, FM: -0.36 ± 0.47, t = 3.48, p = 
0.00008, Figure 2.2C).  
To determine exactly which hubs were altered, we assigned hub status to nodes whose 
degree or betweenness centrality was greater than one standard deviation above the mean, for 
each group separately (Figure 2.3A). See Tables A.6 and A.7 for a list of hub brain regions. FM 
patients had higher degree in the right mid insula, bilateral anterior insula, bilateral superior 
temporal gyrus (STG), left precuneus, right inferior temporal gyrus, and the right inferior parietal 
lobule.  HCs had higher degree in left primary somatosensory cortex (S1), left middle temporal 
gyrus and five nodes in the visual cortex (Figure 2.3B). Results for betweenness centrality were 
similar (Figure 2.3C) and all differences are listed in Table 2.1.  
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Figure 2.2. Large scale hub reorganization in FM. The hub disruption index (κ) measured by (A) degree (κD), (B) betweenness 
centrality (κBC) and (C) participation coefficient (κPC) is plotted as the mean value of each node in HC (x axis) versus the 
difference between FM and HC for each corresponding node (y axis). A negative slope (κ) indicates that hubs in HC are 
decreased in FM and non-hubs in HC have increased hubness in FM.  Boxplots showing each participants κ value are plotted for 
each measure. Across all measures, the anterior insula has shown an increase in hub strength in FM patients, while the visual 
cortex hub strength has decreased. FM, fibromyalgia; HC, healthy control; M1, primary motor cortex; S1, primary 
somatosensory cortex; STG, superior temporal gyrus, Ant Ins, anterior insula; Mid Ins, mid insula; Precun, precuneus; V1, 
primary visual cortex; V2, secondary visual cortex; V3, visual association cortex; SFG, superior frontal gyrus 
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Figure 2.3. Altered hub topology in FM. Hubs were defined for each group separately as greater than one standard deviation 
above the mean group degree or betweenness centrality. All FM and HC hubs, as defined by degree, are depicted in (A). Between 
group differences in hub regions were assessed using non-parametric permutation testing for (B) degree, (C) betweenness 
centrality, and (D) participation coefficient.  The anterior insula consistently had significantly stronger hub status in FM patients 
across all measures. Hubs can be further classified based on the level of inter- versus intra-modular connectivity. Connector 
hubs have connections to many different functional systems, while provincial hubs have connections mainly within the same 
system. Connector and provincial hubs and are depicted for FM and HC in (E). The anterior insula is also a connector hub in 
FM. FM, fibromyalgia; HC, healthy control; S1, primary somatosensory cortex; SMA, supplementary motor area; SMG, 
supramarginal gyrus; V1, primary visual cortex; V2, secondary visual cortex; V3, visual association cortex; PCC, posterior 
cingulate; Precun, precuneus; SPL, superior parietal lobule; IPL, inferior parietal lobule; STG, superior temporal gyrus; IFG, 
inferior frontal gyrus; MCC, mid cingulate cortex; SFG, superior frontal gyrus; ITG, inferior temporal gyrus; Ant Ins, anterior 
insula; Mid Ins, mid insula 
 
 
 
	   43	  
Table 2.1: Differences in hub strength between FM patients and HCs 
 
 Brain Region (Node #) HC 
(mean ± SD) 
FM 
(mean ± SD) 
t p-value 
Degree 
FM > HC R mid insula (56) 70.40 ± 14.02 77.22 ± 13.83 -1.96 0.05 
 L STG  (58) 69.44 ± 12.81 77.64 ± 14.69 -2.42 0.02 
 L precuneus (166) 61.27 ± 16.74 69.13 ± 14.89 -1.96 0.05 
 R ITG (179) 56.58 ± 10.10 68.48 ± 14.64 -3.94 0.001 
 L anterior insula (208) 62.58 ± 15.21 70.46 ± 15.52 -2.06 0.04 
 R anterior insula  (209) 62.73 ± 14.87 70.22 ± 12.30 -2.16 0.03 
 R anterior insula  (211) 55.90 ± 17.62 65.43 ± 14.80 -2.31 0.02 
 R IPL (235) 63.06 ± 13.59 72.48 ± 13.06 -2.83 0.006 
 R STG (240) 57.80 ± 14.08 68.51 ± 14.50 -3.02 0.004 
HC > FM L S1 (23) 67.16 ± 13.54 60.11 ± 14.53 2.03 0.04 
 L MTG (83) 69.42 ± 14.79 60.04 ± 12.99 2.67 0.009 
 R V1 (141) 71.56 ± 16.58 61.30 ± 13.52 2.67 0.009 
 R V3 (153) 72.71 ± 13.05 64.61 ± 12.85 2.51 0.01 
 R V2 (165) 72.64 ± 10.79 65.05 ± 11.82 2.72 0.008 
 R V3 (169) 67.50 ± 11.42 59.86 ± 15.82 2.29 0.02 
 L V2/V3 (172) 72.67 ± 15.71 62.69 ± 15.67 2.55 0.01 
Betweenness Centrality 
FM > HC R mid insula (56) 388.72 ± 161.53 477.85 ± 151.78 -2.27 0.03 
 L angular (87) 250.20 ± 85.32 351.37 ± 141.23 -3.65 0.001 
 R ITG (179) 284.10 ± 136.62 377.93 ± 182.49 -2.40 0.02 
 R anterior insula (209) 264.38 ± 106.18 327.81 ± 139.77 -2.11 0.04 
 R anterior insula (211) 229.85 ± 113.63 331.08 ± 161.44 -3.01 0.003 
 R IPL (235) 298.21 ± 140.01 382.18 ± 163.62 -2.25 0.03 
 R STG (240) 229.25 ± 97.51 356.00 ± 158.52 -4.05 0.001 
HC > FM R V1 (141) 328.67 ± 177.66 248.07 ± 127.56 2.03 0.04 
 R V3 (169) 316.24 ± 116.45 244.84 ± 98.52 2.62 0.01 
 L V2/V3 (172) 371.17 ± 177.75 261.35 ± 153.61 2.62 0.01 
 R SFG (219) 393.14 ± 171.72 281.26 ± 129.02 2.88 0.005 
 
Table 2.1. Differences in hub strength between FM patients and HCs. FM, fibromyalgia; HC, healthy control; SD, standard 
deviation; R, right; L, left; STG, superior temporal gyrus; ITG, inferior temporal gyrus; IPL, inferior parietal lobule; S1, 
primary somatosensory cortex; MTG, mid temporal gyrus; V1, primary visual cortex; V2, secondary visual cortex; V3, visual 
association cortex; SFG, superior frontal gyrus 
	  
Fibromyalgia Participants Exhibit Altered Connector and Provincial Hubs 
Hubs can be further delineated into provincial or connector hubs based on whether the 
connections are mainly to nodes within the same system, or module, or between nodes in 
different modules (Sporns et al., 2007). In FM patients, the right anterior insula had a 
significantly higher participation coefficient relative to HC (t = -2.14, p = 0.035) and met criteria 
for a connector hub (Figure 2.3D-E).  The mid cingulate and primary motor cortex (M1) were 
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also connector hubs in FM, while these regions were provincial hubs in HC.  In HC, nodes in V1, 
V3 and the SFG were classified as connector hubs. HCs had significantly higher participation 
coefficients in bilateral V2/V3 (right t = 2.83, p = 0.006, t = 2.766, p = 0.007, left t = 2.57, p = 
0.013). In both groups, the precuneus, inferior frontal gyrus and supramarginal gyrus were 
classified as connector hubs and the mid insula, supplementary motor area (SMA) and S1 were 
provincial hubs, although FM patients had significantly higher participation coefficients in left 
S1 (t = -2.20, p = 0.031).   
Altered Rich Club Membership in Fibromyalgia 
Next, we examined higher order rich club classification in patients and controls.  The rich club 
curves for the group averaged networks at 5% density are displayed in Figure 2.4A.  Both FM 
and HC brain networks had a rich club organization, which differed from random networks, but 
the rich club coefficients were not significantly different between groups. In FM, the rich-club 
regime (defined as ϕ (k) significantly different from ϕ random (k), and ϕ norm (k) > 1) was between k 
= 4 to k = 6 and k = 8 to k = 22.  In HC, the rich-club regime was over a range of k = 2 to k = 22.  
The illustrated rich club regions for FM and HC (k = 22; the highest level of k that was 
significantly different from random networks for both groups, which also corresponds to nodes 
with a degree greater than one standard deviation above the group mean) are depicted in Figure 
2.4B & C. While there was no significant difference in the level of rich club organization 
between FM and HCs, the hubs that constituted the rich club were different between groups.  
Most importantly, the bilateral anterior insulae were members of the rich club in FM patients but 
not controls.  Results were similar for most other network densities tested, and are illustrated in 
Figure A.2.  
 
	   45	  
	  
Figure 2.4. Rich Club Membership is altered in FM. (A) Both FM and HC have significant rich club organization compared to 
random networks. The rich club regime (compared to random networks) for FM was between k = 4 and k = 6 and k = 8 and k = 
22, and for HC was between k = 2 and k = 22.  There was no significant difference in the rich club coefficient (ϕ) between FM 
and HC at any k level.  Normalized rich club curves are also depicted which show an increasing ϕ norm over a range of k for both 
groups. However, rich club membership was different between groups. FM and HC rich club nodes are depicted in (B) and (C), 
respectively, for k = 22, the highest significant k level. The FM rich club includes the bilateral anterior insula, whereas the HC 
rich club contains more nodes in the visual cortex. The data depicted are from 5% network density; results are similar for other 
thresholds (See Supplementary Fig. 1). FM, fibromyalgia; HC, healthy control; Ant Ins, anterior insula 
	  
Rich Club Membership is Associated with Clinical Pain 
To determine if rich club membership was related to clinical pain, we divided the FM group into 
age-matched tertiles based on the level of clinical pain on the day of the scan (Figure 2.5). As 
expected, the tertiles had significantly different pain ratings (VAS mean ± SD, high: 7.0 ± 1.2, 
medium: 5.1 ± 1.5, low: 2.5 ± 1.6, F(2,37) = 29.02, p < 10-8).  There were no significant 
differences between the tertiles in age (F(2,37) = 0.55, p = 0.58) or depression (F(2,37) = 1.07, p = 
0.35).  The rich club coefficient, ϕ (k), was not significantly different between the tertiles for any 
level of k; however, the hubs comprising the rich club in each tertile were markedly different.  
The rich club nodes in the high pain group were predominantly in S1/M1, STG, and the anterior 
and posterior insula.  The medium pain group rich club included fewer S1/M1 regions and the 
anterior insula, with a general shift towards more posterior and default mode network (DMN) 
regions.  Finally, the rich club in the low pain group appeared more similar to HC and primarily 
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contained nodes in the frontoparietal, DMN and visual networks.  Results were similar across all 
other thresholds tested and are illustrated in Figure A.3.   
	  
Figure 2.5. Rich club membership varies with clinical pain. The high pain FM group (A) had rich club nodes primarily in 
bilateral S1, M1, SMA and the right posterior insula.  The rich club in the medium pain FM group (B) contained fewer S1/M1 
nodes and more nodes in the default mode network.  In the low pain group (C), there was a shift in rich club membership to 
posterior default mode and visual regions. The data depicted are from 5% network density; results are consistent across 
thresholds (See Supplementary Fig. 2). FM, fibromyalgia; M1, primary motor cortex; S1, primary somatosensory cortex; SMA, 
supplementary motor area 
	  
Differences in eigenvector centrality between FM and HC, and the relationship to clinical pain 
and rich club membership 
To investigate the nature or quality of edges made in the reconstructed brain network, we 
calculated the eigenvector centrality of each node.  The eigenvector centrality accounts for the 
quantity and quality of connections by taking into account the degree of a node and the degree of 
that node’s neighbors.  FM patients, compared to HC, had higher eigenvector centrality in the 
left anterior insula (t = -2.38, p = 0.02), bilateral STG (right t = -1.99, p = 0.049, left t = -2.34, p 
= 0.022), right inferior parietal lobule (t = -2.22, p = 0.03), left precuneus (t = -2.29, p = 0.025), 
and right inferior temporal gyrus (t = -3.01, p = 0.003). HCs had higher eigenvector centrality in 
the left middle temporal gyrus (t = 2.39, p = 0.019), right V1 (t = 1.99, p = 0.049), and right V3 
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(t = 2.15, p = 0.035).  The left anterior insula and STG were members of the rich club in FM, 
while the right V1 and V3 belonged to the rich club in HC.   
 We then correlated the eigenvector centrality with the level of clinical pain in FM 
patients.  The eigenvector centrality of 14 nodes in bilateral S1/M1, three nodes in the bilateral 
STG, two nodes in the right posterior insula, and one node each in the right SMA and right 
supramarginal gyrus positively correlated with clinical pain (all r > 0.3, p < 0.05, Figure 2.6 and 
Table A.8).  Five of these nodes (three in bilateral M1, one in the supramarginal gyrus, and one 
in the right posterior insula) belonged to the rich club only in the high pain FM tertile. 
 
Figure 2.6. Correlations with clinical pain in FM. (A) Within FM patients, there were positive correlations between clinical pain 
and eigenvector centrality (a measure of how connected a brain region is to other highly connected regions) in 14 bilateral 
S1/M1 nodes, three nodes in right STG, two nodes in the right posterior insula, and one node each in the right SMA, and right 
SMG. Representative correlations are shown in (B) for left M1/operculum and right M1/S1 and regression lines for all 21 
correlations are depicted in (C). FM, fibromyalgia; M1, primary motor cortex; S1, primary somatosensory cortex; STG, superior 
temporal gyrus; SMA, supplementary motor area; SMG, supramarginal gyrus; VAS, visual analog scale. 
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Graph Theory Metrics Mediate the Relationship between Glutamate within the Posterior Insula 
and Clinical Pain Intensity. 
As the right posterior insula was a member of the rich club in FM patients with the highest levels 
of clinical pain, we sought to examine the relationship between hub strength, clinical pain and 
Glx.  Right posterior insula Glx (CSF corrected values) was significantly different between the 
FM pain tertiles and HC (F(3,62) = 4.37, p = 0.007). Specifically, the high pain group had 
significantly higher Glx in the right posterior insula compared to the low pain group (mean ± SD 
high: 12.76 ± 1.13, low: 11.20 ± 1.42, p = 0.013) and compared to HC (mean ± SD HC: 10.97, p 
= 0.001).  
Two nodes overlapped with the 1H-MRS voxel in the right posterior insula (Figure 2.7A).  
The standardized and averaged eigenvector centrality of these two posterior insula nodes 
positively correlated with clinical pain (r = 0.419, p = 0.008, Figure 2.7B) and Glx (r = 0.320, p 
= 0.05; Figure 2.7B).  In mediation analyses, higher posterior insula Glx was associated with 
greater clinical pain indirectly through increased averaged posterior insula eigenvector centrality 
(B = .132; 95% CI= .016, .399).  The direct effect of insula Glx on clinical pain was also 
significant (B= .387, p = .026).  The R2 value for clinical pain in this model was .422. See Figure 
2.7C for standardized estimates and confidence intervals of each path in the model.   
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Figure 2.7. The relationship between clinical pain, eigenvector centrality and posterior insula Glx. (A) Glutamate + glutamine 
(Glx) was measured in the right posterior insula using 1H-MRS (voxel shown in dark gray).  The overlap between the 1H-MRS 
voxel and 2 nodes from the Power’s atlas is shown in the inset. (B) In FM, clinical pain and posterior insula Glx positively 
correlated with the averaged, standardized eigenvector centrality in these 2 posterior insula nodes. (C) In a mediation analysis, 
posterior insula eigenvector centrality significantly mediated the relationship between Glx in the posterior insula and clinical 
pain.  Standardized values are shown for ease of interpretation.   FM, fibromyalgia; Glx, glutamate + glutamine; SM, 
sensorimotor network; EC, eigenvector centrality; H-MRS, proton magnetic resonance spectroscopy; AIU, arbitrary institutional 
units 
	  
Discussion 
In this study we have shown that hubs, the brain regions that create efficiency and route 
information across networks, are altered in FM patients.  Brain regions that were hubs in FM, 
such as the anterior insula and STG, were non-hubs with low degree or centrality in HCs. 
Conversely, hubs in HCs, such as the visual cortex and SFG, were non-hubs in FM patients. We 
also found a reorganization of nodes with high between-network connectivity.  In FM, nodes in 
the anterior insula, S1 and M1 had the greatest increase in participation coefficient relative to the 
HC group.  In HCs, the nodes with the highest participation coefficient were again in the visual 
cortex and cuneus. The anterior insulae were consistently ranked as hubs in the FM group and 
were significantly different from HCs on multiple measures, indicating that the anterior insulae 
had more connections, were more central to information flow, and were more connected to other 
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nodes with high degree and nodes outside its own module.  We also examined a higher-order hub 
structure (the rich club) and found that rich club membership was altered in FM and varied with 
the level of clinical pain.  Finally, this study demonstrates, for the first time to our knowledge, a 
neurochemical correlate of altered hub topology and its relationship to the perception of pain.  
Taken together, these data suggest that, within the chronic pain network, the brain regions most 
crucial for information processing and integration are located in regions such as the insulae that 
are known to be pro-nociceptive.   
Physical and biological systems share an optimal pattern of network organization that is 
characterized by high clustering, short average path length, hierarchical modularity, scale-free 
degree distribution and highly interconnected hub nodes, which together form a rich club. In the 
case of the brain, this optimal topology is consistently disrupted in disease states. However, there 
is little consensus within each disorder as to the specific nature of this network disruption (Stam, 
2014). From all the organizational principles listed above, one consistent finding has been 
abnormalities in hub topology, which have been reported for a range of neurological disorders, 
including schizophrenia (Crossley et al., 2016; Lynall et al., 2010; Rubinov and Bullmore, 2013; 
van den Heuvel et al., 2013), Huntington’s disease (Harrington et al., 2015), Alzheimer’s disease 
(Buckner et al., 2009; Dai et al., 2015) and depression (Wu et al., 2016) (see (Crossley et al., 
2014) for recent meta-analysis).  
Previous studies have examined network connectivity and topology in other chronic pain 
conditions. A study of chronic back pain patients found increased functional connectivity 
between hubs in the DMN and the insula relative to HCs (Tagliazucchi et al., 2010). Similarly, 
increased cross-network communication between the DMN and the salience network was found 
in patients with chronic pain due to ankylosing spondylitis, which also correlated with the level 
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of clinical pain (Hemington et al., 2015).  The most comprehensive analysis to date found altered 
whole-brain degree rank order in three different chronic pain populations relative to HCs 
(Mansour et al., 2017).  Additionally, the level of disruption correlated with the level of clinical 
pain. However, this study did not examine hubs specifically.  Instead, it assessed the modular 
structure of the network and the variability in community membership. The insula was a member 
of the sensorimotor network in the majority of HCs; however, allegiance in chronic pain 
conditions was split between the sensorimotor, default mode and subcortical networks. Our 
finding of increased hub strength and inter-network communication in the anterior insula in FM 
relative to HCs is consistent with these studies. 
A key attribute of brain networks is the existence of a rich club organization, in which 
high degree hubs form a densely interconnected core.  The rich club may also serve to integrate 
information from different modules in the brain since rich club hubs are often distributed across 
the brain and include many different resting state networks (van den Heuvel and Sporns, 2011). 
In the current study, we found both FM and HC networks possessed, by global assessment, a 
similar level of rich club organization.  However, the specific membership of the rich club varied 
between groups - the visual network was dominant in HCs, while a more distributed organization 
was present in FM that included the bilateral anterior insulae.  The rich club visual nodes in HCs 
formed a stand-alone network, which is consistent with previous studies showing a low level of 
integration in the functional rich club of healthy adults (Grayson et al., 2014).  It is interesting to 
note that in FM, the visual nodes were integrated into the rest of the rich club.  Balenzuela and 
colleagues reported a disruption in the community membership in chronic back pain patients 
such that the insula was abnormally integrated into the auditory system and dorsal visual stream 
(Balenzuela et al., 2010). Given our previous findings of visual hypersensitivity and increased 
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insular activation during an unpleasant visual stimulus in FM (Harte et al., 2016), it is possible 
that altered rich club membership and integration contributes to the phenomenon of multi-modal 
sensory sensitivity observed in many chronic pain patients.   
In an analysis of functional hubs in migraine, the insula, S1, M1 and the orbitofrontal 
cortex were the most strongly interconnected regions and members of the rich club in patients 
with the longest disease duration compared to HCs (Liu et al., 2015).  This is consistent with our 
findings but this previous study did not examine the relationship of rich club membership and 
clinical pain. Within our FM patients, rich club membership varied as a function of clinical pain.  
In general, the distribution of rich club nodes shifted from the default mode, frontoparietal and 
visual networks in the low pain FM group, to the sensorimotor, cingulo-opercular and salience 
networks in the high pain FM group.  Patients with the highest levels of clinical pain had rich 
club nodes mainly in S1, M1, SMA, STG, operculum, anterior and posterior insula.  The high 
pain rich club had just one DMN node and seven nodes in the visual network, while the low pain 
group had 13 DMN and 20 visual network regions. Overall, the low pain rich club resembled 
HCs more closely than the high pain rich club. This suggests that the intensity of chronic pain is 
related to, and perhaps determined by, rich club membership. 
Although the posterior insula did not meet hub criteria in the FM group, the connectivity 
of this structure with other highly connected nodes (as measured with eigenvector centrality) was 
positively correlated with the level of ongoing clinical pain. The right posterior insula was a 
member of the rich club only in the high pain FM tertile. We previously showed that posterior 
insula Glx is elevated in FM patients relative to HCs (Harris et al., 2009).  Here we found that 
posterior insula Glx was significantly higher in the high pain tertile compared to the low pain FM 
group.  Importantly, we demonstrated that eigenvector centrality of nodes, within the posterior 
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insula region showing elevated Glx, mediates the relationship between this neurotransmitter and 
clinical pain. Thus, altered neurochemistry in an individual hub could alter functional network 
properties that result in the experience of pain.  This is consistent with recent preclinical studies 
in rodents demonstrating a causal influence of excitatory-inhibitory balance in the insula on pain 
(Harte et al., 2017; Watson, 2016).  
Why might hubs be preferentially affected in chronic pain? Stam hypothesized that since 
hubs are damaged or reorganized in many different neurological disorders, there must be a 
general mechanism that makes hub brain regions more vulnerable (Stam, 2014). Briefly, he 
suggests that, in the acute phase, traffic to a failing node is rerouted to existing hub regions, 
which become overloaded.  This would be observed as an increase in the degree or centrality of 
hubs relative to healthy networks. In the chronic phase, new hubs appear to avoid or compensate 
for hub overload. This would be reflected as a decrease in the degree or centrality of “healthy” 
hubs and the appearance of new hubs.  
In the chronic pain patients studied here, we demonstrated an appearance of new hubs 
(anterior insula, STG) and a disappearance of “healthy” hubs (visual cortex, SFG).  This may be 
due to a barrage of nociceptive input, although this is unlikely given the lack of convincing 
evidence of peripheral pathology in FM (Clauw, 2014).  It is more likely that the reorganization 
of hubs stems from an underlying alteration in excitatory neurotransmission in pro-nociceptive 
brain regions (Watson, 2016). The mediation analyses described here were consistent with a 
model in which higher levels of Glx in the posterior insula increase the eigenvector centrality of 
posterior insular nodes and, consequently, clinical pain.  Longitudinal analyses will be required 
to determine if these effects are in fact causal in chronic pain patients. 
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Our study has limitations. First, a general methodological limitation of graph theoretical 
analyses is the arbitrary thresholding and binarization process, which leads to the loss of 
information, specifically, anticorrelations.  However, binary networks, such as those used here, 
retain the most significant correlations and may be less sensitive to noise and therefore easier to 
interpret (Rubinov and Sporns, 2010). We examined a relatively small number of female 
participants with FM, so it remains unknown if our findings are generalizable to males or other 
chronic pain conditions. Additionally, many of the FM patients studied here were taking 
medications to manage their symptoms and it is unclear how these treatments may be impacting 
our results.  Future studies are necessary to replicate our findings in larger sample sizes using 
fully weighted networks.  
 In conclusion, we demonstrated altered hub topology in FM patients, and showed that 
disruptions in the excitatory tone within the insula altered the strength of this region as a hub and 
was associated with the intensity of clinical pain.   Although cross-sectional in nature, these data 
suggest the possibility that disruption and reallocation of rich club hub membership plays a 
causal role in the symptomatology of a common chronic pain condition. 
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Chapter 3 : Changes in Resting State Functional Connectivity after Repetitive 
Transcranial Direct Current Stimulation Applied to Motor Cortex in 
Fibromyalgia Patients1 
Introduction 
Fibromyalgia (FM) is a chronic centralized pain condition characterized by widespread 
pain, fatigue, sleep problems, cognitive dysfunction, and mood disturbances (Wolfe et al., 1990). 
While the exact pathophysiology of FM remains unknown, a prevailing hypothesis states that a 
sensory processing dysfunction within the central nervous system creates, amplifies, or sustains 
the perception of chronic pain (Schmidt-Wilcke and Clauw, 2011). In support of this hypothesis, 
brain network alterations seen in these patients fall into two broad categories: decreased 
descending anti-nociceptive transmission, and/or enhanced pro-nociceptive processing (Jensen et 
al., 2009; Napadow et al., 2010; Jensen et al., 2012; Napadow et al., 2012). 
Motor cortical dysfunction has been suggested in a number of chronic pain conditions, 
including FM. In general, the primary motor cortex (M1) shows increased cortical excitability at 
baseline and heightened responses to sensory stimuli, which may be suggestive of a reduction in 
inhibitory activity (Saavedra et al., 2014). Noninvasive brain stimulation has emerged as an 
attractive therapeutic option for chronic pain conditions given its ability to target specific cortical 
regions. Some studies report that transcranial direct current stimulation (tDCS) over M1 relieves 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  This chapter was previously published in the journal Arthritis Research & Therapy: Cummiford, C. M., 
Nascimento, T. D., Foerster, B. R., Clauw, D. J., Zubieta, J. K., Harris, R. E., & DaSilva, A. F. (2016). Changes in 
resting state functional connectivity after repetitive transcranial direct current stimulation applied to motor cortex in 
fibromyalgia patients. Arthritis Res Ther, 1–12. http://doi.org/10.1186/s13075-016-0934-0 
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pain in FM (Fregni et al., 2006; Valle et al., 2009; Fagerlund et al., 2015). However, a recent 
review did not find a significant difference between sham and real M1 tDCS on short-term pain 
relief (O'Connell et al., 2014).  The lack of effect may be due to significant heterogeneity 
between the studies (i.e., stimulation parameters, number of treatment sessions, type of chronic 
pain) included in the review. It is also possible that sham tDCS produces a significant placebo 
response. Consistent with previous work implicating the endogenous opioid system in placebo 
analgesia (Petrovic, 2002; Wager et al., 2007), we recently showed that sham tDCS caused the 
release of endogenous opioids in the PAG, precuneus and thalamus (DosSantos et al., 2014). 
While placebo responses are clearly present in tDCS, the specific neurobiology 
underlying the analgesic effects of real tDCS are less clear. During and immediately after 
stimulation, tDCS may alter excitability by modulating resting membrane potential.  Longer 
lasting effects may be due to changes in synaptic plasticity via mechanisms similar to long-term 
potentiation or depression (Dayan et al., 2013).  M1 tDCS can alter the functional connectivity 
(FC) of regions under the stimulating electrode (Polanía et al., 2012a), as well as spatially distant 
but structurally connected regions, such as the thalamus (Polanía et al., 2012b) and DLPFC 
(Sehm et al., 2012; Lindenberg et al., 2013). Real tDCS also acts on the endogenous opioid 
system (DosSantos et al., 2014), similar to invasive motor cortex stimulation (Maarrawi et al., 
2007; 2013). However, these studies were conducted in healthy participants and examined FC 
during or shortly after M1 tDCS. There have been no investigations of how M1 tDCS alters 
resting state FC in chronic pain patients treated repeatedly, as they might be in clinical practice.  
We measured clinical pain and resting state FC in twelve FM patients at baseline, after 
five days of sham and after five days of real tDCS.  We were interested in three questions: Does 
baseline connectivity predict clinical treatment response? Are there differences in FC after sham 
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and real tDCS? And do changes in FC relate to analgesia? We hypothesized that strong M1 – 
thalamus connectivity at baseline would predict a better clinical response, as shown in previous 
M1 stimulation studies (Goto et al., 2008; Ohn et al., 2012). In addition, since we found a trend 
towards decreased glutamate + glutamine (Glx) in the thalamus after real tDCS in these same 
patients (Foerster et al., 2014), and given the strong structural connectivity between M1 and the 
thalamus (Zhang et al., 2010), we hypothesized that real tDCS would decrease FC between the 
thalamus and brain regions involved in pain perception.  
Patients and Methods 
Patients. We recruited thirteen female patients with FM (age 27-64, mean ± SD: 47.6 ± 10.6 
years) for this study. One patient dropped out after the baseline visit, the remaining twelve 
patients completed the entire protocol.  All patients met the 1990 criteria of the American 
College of Rheumatology for FM (Wolfe et al., 1990), had symptoms for at least one year and 
reported pain on more than 50% of days.  Inclusion criteria were: right-handed, a BMI of 36 or 
less and agreement to delay taking new medications or treatments for FM during the study.  
Exclusion criteria were: pregnant or breastfeeding, participation in other clinical trials, currently 
taking opiates, history of autoimmune or chronic inflammatory disease that causes pain, 
substance abuse or severe psychiatric illness, and contraindications with magnetic resonance 
imaging procedures. The University of Michigan Institutional Review Board approved this study 
and all subjects gave written informed consent. The effect of tDCS on brain metabolites in these 
same subjects is described in a previous report (Foerster et al., 2014). 
Study Design. Our within-subjects crossover design had three phases: a baseline pain 
assessment and functional magnetic resonance imaging (fMRI) session #1, sham tDCS for five 
consecutive days followed by pain assessment and fMRI #2, and real tDCS for five consecutive 
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days followed by pain assessment and fMRI #3 (Figure B.1). Sham and real tDCS phases were 
separated by a 7-11 day washout period (mean = 9.9 days). We chose to perform real tDCS for 
five consecutive days because previous studies in FM patients have shown a meaningful 
reduction in clinical pain using this protocol (Fregni et al., 2006; Fagerlund et al., 2015). We did 
not use a randomized design in order to limit carry over from real to sham tDCS (Brunoni and 
Fregni, 2011). All participants were debriefed during a final follow-up visit. Patients were also 
offered a clinical referral for an outpatient clinic at our institution for continuation of care with 
regular therapy for their symptoms. 
Clinical Pain Outcomes. Clinical pain intensity was assessed as an “average” experience for the 
week before each assessment using a visual analog scale (VAS), with 0 being “no pain” and 10 
being the “worst possible pain”. Clinical pain was also assessed using the short-form McGill 
Pain Questionnaire (Melzack, 1987) and affective state was measured using the Positive and 
Negative Affect Schedule (PANAS) (Watson et al., 1988). We are missing McGill baseline pain 
data for one patient, PANAS scores across all conditions for one patient and PANAS baseline 
only scores for two patients.  Clinical results have been published previously (Foerster et al., 
2014) and are reproduced in Table B.1. Differences in clinical variables across conditions were 
assessed with repeated measures ANOVA in SPSS v22.  Significance was set at an alpha level of 
p < 0.05. The changes in clinical pain scores used in neuroimaging analyses were calculated by 
subtracting sham – baseline VAS and real – sham VAS. 
tDCS Protocol. The tDCS protocol was performed as described previously (DaSilva et al., 
2011).  Briefly, for both sham and real tDCS sessions, the anode electrode was placed on the 
scalp over the left motor cortex and the cathode over the right supraorbital cortex. Positions were 
determined individually using the EEG 10/20 system, respectively C3 and FP2. Electrodes were 
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placed by the same operators (AFD and TDN) for all patients. Active stimulation consisted of 2 
mA of current applied continuously for 20 minutes. During sham tDCS, the current was applied 
for 30 seconds at the beginning and end of the session.  Patients were blinded to type (i.e. real vs. 
sham) of treatment they were receiving. This protocol is identical to that used in previous studies 
of M1 tDCS in FM patients (Fregni et al., 2006; Fagerlund et al., 2015).  
Neuroimaging Methods. Resting state fMRI sessions were performed on a Philips Ingenia 3T 
system (Best, Netherlands) with a 15 channel receive head coil.  Each scan lasted 10 minutes and 
parameters include: a T2*-weighted BOLD echo-planar imaging (EPI) sequence (TR=2000ms, 
TE=30ms, flip angle 77 degrees, 30 slices, voxel size = 3.44 x 3.33 x 4.00mm). Physiological 
data (cardiac and respiratory volume) were collected simultaneously. A high-resolution structural 
image was acquired for normalization purposes (TR/TE = 9.8/4.6 ms, flip angle 8 degrees, 151 
slices, voxel size = 1 x 1 x 1 mm). fMRI data were checked for quality and head motion greater 
than 3 mm; no data were excluded. Resting state fMRI data was preprocessed using SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) running on Matlab R2010a (Mathworks, 
Sherborn, MA, USA) and included physiological artifact correction, slice timing correction, 
realignment, coregistration, normalization to MNI space and smoothing (FWHM=8mm).   
Seed-to-whole brain FC analyses were performed using the Conn Toolbox (Whitfield-
Gabrieli and Nieto-Castanon, 2012). Seeds were chosen based on the following criteria: 1) 
location under stimulating anode (left precentral gyrus and left postcentral gyrus (M1/S1), WFU 
PickAtlas, http://www.nitrc.org/projects/wfu_pickatlas), 2) structural connectivity to left M1 and 
S1 (right pre and postcentral gyri, bilateral ventral lateral (VL) and ventral posterior lateral 
(VPL) thalamus, WFU PickAtlas), and 3) our previous tDCS studies (PAG (DosSantos et al., 
2014)).  The time-series for each seed region was extracted and white matter, cerebrospinal fluid 
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signal and realignment parameters were entered into the analysis as regressors of no interest. A 
band-pass filter (.008-.09 Hz) was applied to remove linear drift artifacts and high-frequency 
noise. First level analyses were performed by correlating the time series from each seed region 
with the rest of the voxels in the brain, creating seed-to-whole-brain Fisher-transformed 
correlation maps.  These maps were imported into SPM8 for group level analyses.   
For prediction analyses, we performed seed-to-whole brain regression analyses with 
baseline FC maps and change in clinical pain (real – baseline) as a regressor of interest.  Main 
effects were calculated using repeated measures ANOVA design with baseline, sham and real 
tDCS FC maps.  The contrasts of interest were baseline versus sham, and sham versus real tDCS. 
We also examined the change in FC across the entire study using the contrast baseline versus real 
tDCS. To examine correlations between changes in connectivity and changes in clinical pain, we 
first created difference images by subtracting first level connectivity maps for each subject (sham 
– baseline, real – sham, real – baseline). We then preformed a regression analysis with VAS 
change scores as a regressor of interest. All analyses controlled for differences in age. Results 
were thresholded at uncorrected p<0.001 on the voxel level and p<0.05 FWE correction for 
multiple comparisons at the cluster level with a cluster size of > 5 voxels.  For a-priori regions 
that did not meet this stringent threshold, we performed small volume corrections (SVC) using 
the anatomically (WFU PickAtlas) defined ROIs used as seed regions or functionally defined 
ROIs from our previous findings in FM (Napadow et al., 2010). Significance for SVC was set at 
p<0.05 FWE at the cluster level with a cluster size of > 5 voxels. The Fisher-transformed 
correlation values were extracted using MarsBaR software (http://marsbar.sourceforge.net) and 
post-hoc analyses performed in SPSS v22.   
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Results 
Clinical Pain Reduction with Sham and Real tDCS 
As reported previously (Foerster et al., 2014), there was a trend towards improvement in 
VAS clinical pain during the sham period (mean difference ± SE, sham minus baseline: -1.042 ± 
0.572; 95% CI: -0.218 to 2.301; p = 0.096), and there was no significant difference in pain relief 
between sham and real tDCS (mean difference ± SE, real minus sham: -0.750 ± 0.494; 95% CI: -
1.838 to 0.338; p = 0.157). However, clinical pain significantly decreased across the entire study 
from baseline to after real tDCS (mean difference ± SE real minus baseline: -1.792 ± 0.762; 95% 
CI: -3.470 to -0.114; p = 0.038). There were no significant differences in clinical pain as 
measured by the McGill Pain questionnaire or PANAS positive affect.  There was a significant 
difference between baseline and real tDCS in PANAS negative affect (mean difference ± SE real 
minus baseline: -3.0 ± 1.067; 95% CI: -5.461 to -0.539; p = 0.023). Clinical results for each 
patient individually across the study are presented in Table B.2. 
Stronger Baseline FC is Associated with Subsequent Analgesia 
 To examine common predictive ability of baseline FC for reductions in pain across sham 
and real tDCS (as this was where the significant clinical effect on pain was found), we used pre-
defined ROIs and correlated baseline FC with improvements in clinical pain across the entire 
study period (real – baseline).  Patients who had stronger connectivity at baseline between the 
left M1 seed and left VL thalamus (p = 0.011 FWE, SVC), between the left S1 seed and left 
anterior insula (p = 0.001 FWE), and between the left VL thalamus seed and PAG (p = 0.007 
FWE, SVC) had greater improvement in clinical pain scores across sham and real tDCS periods 
(Figure 3.1 and Table 3.1).  Importantly, these correlations were also significant when looking at 
change in clinical pain from baseline to sham or from sham to real tDCS alone (with one 
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exception: left VL – PAG baseline FC and real – sham clinical pain, p = 0.057; Table B.3). There 
were no regions that showed significant correlations between less connectivity at baseline and 
better treatment response (Figure B.2). In post-hoc analyses, there were no significant 
correlations between baseline connectivity of these regions and the change McGill clinical pain 
or the change in positive and negative affect.  
	  
Figure 3.1. Stronger FC at baseline predicts analgesia. A, Patients with higher L M1 (seed in white) – L VL (anatomical region 
outlined in black) connectivity at baseline had a greater reduction in clinical pain across sham and real tDCS periods (displayed 
at p = 0.005). B, Stronger L S1 (seed in white) – L anterior insula FC at baseline predicted a better clinical response. C, 
Connectivity between the L VL thalamus (seed in white) and the PAG at baseline also predicted patients that would respond to 
sham and real tDCS treatment. M1, primary motor cortex; VL, ventral lateral; S1, primary somatosensory cortex; PAG, 
periaqueductal gray; VAS, visual analog scale; L, left; R, right; FC, functional connectivity (fisher-transformed r-values). 
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Table 3.1. Predicting changes in clinical pain from baseline FC 
Seed 
FC Region 
MNI coordinates 
(x y z) 
r value T Cluster 
size 
Cluster p-value 
        
L M1        
L VL thalamus -18 -14 12 -0.938 5.41 7 0.011 FWE* 
L S1        
L anterior insula -42 14 2 -0.961 9.38 396 0.001 FWE 
L VL thalamus        
PAG -6 -26 -8 -0.929 5.25  8 0.007 FWE*  
 
Table 3.1. Predicting changes in clinical pain from baseline FC. FC, functional connectivity; L, left; M1, primary motor cortex; 
VL, ventral lateral; S1, primary somatosensory cortex; PAG, periaqueductal gray; MNI, Montreal Neurological Institute 
* = Significant at p < 0.05 with small volume correction 
	  
Sham tDCS is Associated with Decreases in FC 
Since previous studies have shown a placebo analgesic response on experimental and 
clinical pain during sham tDCS (Vaseghi et al., 2014), we examined whether sham tDCS 
changed resting state FC (sham – baseline, Table 3.2). After five sessions of sham tDCS, FM 
patients had reduced FC between the left VPL thalamus seed and left S1 (p = 0.016 FWE), left 
amygdala/parahippocampal gyrus (p = 0.004 FWE) and right inferior parietal lobule (IPL, p = 
0.013 FWE; Figure 3.2A). FC also decreased between the right VPL thalamus seed and left IPL 
(p = 0.049 FWE; Figure 3.2B), between the PAG seed and precuneus (p = 0.001 FWE; Figure 
3.2C), and between the right M1 seed and right cerebellum (p = 0.002 FWE).  There were no 
significant increases in FC after sham compared to baseline (Figure B.3).  
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Table 3.2. Main effect of sham tDCS on FC 
 
Seed 
FC Region 
MNI coordinates 
(x y z) 
T Cluster size Cluster p-value 
Baseline > Sham       
L VPL       
L S1 -62 -16 42 6.80 304 0.016 FWE 
L parahipp/amyg -32 -14 -26 6.70 408 0.004 FWE 
R IPL  44 -36 32 5.69 320 0.013 FWE 
R VPL       
L IPL -34 -36 34 5.28 230 0.049 FWE 
R M1 (precentral gyrus)       
R cerebellum 16 -74 -36 5.91 485 0.002 FWE 
PAG       
precuneus -20 -84 24 4.88 618 0.000 FWE 
Baseline < Sham       
N.S.       
 
Table 3.2. Main effect of sham tDCS on FC. tDCS, transcranial direct current stimulation; FC, functional connectivity; L, left; R, 
right; VPL, ventral posterior lateral; S1, primary somatosensory cortex; parahipp/amyg, parrahippocampal gyrus & amygdala; 
IPL, inferior parietal lobule; M1, primary motor cortex; PAG, periaqueductal gray; N.S., not significant; MNI, Montreal 
Neurological Institute 
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Figure 3.2. Sham tDCS decreases FC compared to baseline. A, Decreased connectivity between the left VPL (seed in white) and 
left S1, left parahippocampal gryus and amygdala after sham tDCS compared to baseline. Plots show changes in FC from 
baseline to after the sham treatment period for each FM patient. B, Decreased connectivity between the right VPL (seed in white) 
and left IPL. C, Decreased connectivity between the PAG (seed in white) and precuneus. VPL, ventral posterior lateral; S1, 
primary somatosensory cortex; parahipp, parahippocampal gyrus; amyg, amygdala; IPL, inferior parietal lobule; PAG, 
periaqueductal gray; L, left; R, right; FC, functional connectivity (fisher transformed r-values). 
	  
 To determine if changes in FC related to changes in clinical pain during the sham period, 
we ran a regression analysis with each participants connectivity difference map (sham – 
baseline) with change in VAS (sham – baseline) as a regressor of interest (Table 3.3).  The 
change in connectivity between the left VL thalamus seed and the left posterior insula was 
positively correlated with change in clinical pain (p = 0.001 FWE); patients with reduced 
connectivity between the left VL thalamus and posterior insula had a greater reduction in pain 
intensity after sham tDCS (Figure 3.3A). Reduced connectivity between the right VPL thalamus 
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seed and right M1 (p = 0.001 FWE), right S1 (p = 0.008 FWE) and left M1 (p = 0.046 FWE) also 
correlated with reduced pain after sham tDCS (Figure 3.3B).  Decreased FC between the right S1 
seed and the cerebellum (p = 0.001 FWE) was also positively correlated with change in pain.  
These changes in connectivity were not significantly correlated with changes in positive and 
negative affect or McGill clinical pain. There were no significant relationships between increases 
in connectivity and decreases in clinical pain (Figure B.4).  
 
Table 3.3. Correlations between change in FC and change in clinical pain (VAS) for sham 
vs baseline 
Seed 
FC Region 
MNI coordinates 
(x y z) 
r value T Cluster 
size 
Cluster p-value 
        
L VL thalamus        
L posterior insula -48 -12 0 0.979 12.33 313 0.001 FWE 
R VPL thalamus        
R M1 56 -12 42 0.969 9.85 603 0.000 FWE 
R S1 44 -34 54 0.917 7.46 235 0.008 FWE 
L M1 -46 -6 26 0.936 9.41 158 0.046 FWE 
R S1 (postcentral gyrus)        
cerebellum 36 -52 -20 0.937 7.63 355 0.001 FWE 
 
Table 3.3. Correlations between change in FC and change in clinical pain (VAS) for sham vs baseline. FC, functional 
connectivity; VAS, visual analog scale; L, left; R, right; VL, ventral lateral; VPL, ventral posterior lateral; M1, primary motor 
cortex; S1, primary somatosensory cortex; MNI, Montreal Neurological Institute 
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Figure 3.3. Correlations between changes in FC and changes in clinical pain after sham tDCS. A, Decreased FC between the left 
VL thalamus (seed in white) and left posterior insula was correlated with a reduction in clinical pain after sham tDCS. B, 
Decreased FC between the right VPL thalamus (seed in white) and left M1, right M1, and right S1 correlated with reduced 
clinical pain after sham tDCS.  VL, ventral lateral; VPL, ventral posterior lateral; M1, primary motor cortex; S1, primary 
somatosensory cortex; VAS, visual analog scale; L, left; R, right; FC, functional connectivity (fisher transformed r-values). 
	  
Real tDCS is Also Associated with Decreases in FC 
Next, we measured changes in FC between sham and real tDCS (Table 3.4).  After real 
tDCS, FC decreased between the left VL thalamus seed and the medial prefrontal cortex (mPFC, 
p = 0.006 FWE) and left supplementary motor area (SMA, p = 0.043 FWE; Figure 3.4A). FC 
also decreased between the right VL thalamus seed and the cerebellum (p = 0.001 FWE) and left 
SMA (p = 0.016 FWE; Figure 3.4B).  There were no significant increases in FC (Figure B.3). 
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Table 3.4. Main effect of real tDCS on FC 
Seed 
FC Region 
MNI coordinates 
(x y z) 
T Cluster size Cluster p-value 
Sham > Real       
L VL thalamus       
mPFC 4 56 8 5.66 362 0.006 FWE 
L SMA -2 24 56 5.49 228 0.043 FWE 
L OFG -10 40 -22 5.91 185 0.08 FWE** 
R VL thalamus       
cerebellum 16 -46 -22 6.88 1122 0.000 FWE 
L SMA -6 22 58 6.16 313 0.016 FWE 
Sham < Real       
N.S.       
 
Table 3.4. Main effect of real tDCS on FC. tDCS, transcranial direct current stimulation; FC, functional connectivity; L, left; R, 
right; VL, ventral lateral; mPFC, medial prefrontal cortex; SMA, supplementary motor area; OFG, orbitofrontal gyrus; N.S., not 
significant; MNI, Montreal Neurological Institute; ** = Trend at p < 0.05 FWE correction for multiple comparisons 
	  
	  
	  
Figure 3.4. Real tDCS decreases FC compared to sham. A, Decreased connectivity between the left VL (seed in white) and SMA 
and mPFC after real tDCS. Plots show changes in FC between sham and real tDCS for each FM patient. B, Decreased 
connectivity between the right VL (seed in white) and SMA and cerebellum after real tDCS. VL, ventral lateral; SMA, 
supplementary motor area; mPFC, medial prefrontal cortex; L, left; R, right; FC, functional connectivity (fisher transformed r-
values). 
	  
When comparing baseline to real tDCS, we found significant decreases in connectivity 
between the left VPL thalamus seed and the left IPL (p = 0.041 FWE) and between the PAG 
seed and the posterior cingulate (p = 0.007 FWE; Figure B.4 and Table B.4).  There were no 
significant increases in FC. 
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 We did not find any regions that met whole brain correction in a regression analysis 
measuring changes in connectivity in relation to changes in pain after real tDCS compared to 
sham, however there were regions that met significance using SVC with a-priori ROIs (Table 
3.5).  The change in connectivity between the left VPL thalamus and left M1/S1 (p = 0.007 
FWE, SVC) and right posterior insula (p = 0.007 FWE, SVC) was positively correlated with the 
change in clinical pain (Figure 3.5). The change in left VL thalamus to right posterior insula 
connectivity was also positively correlated with change in pain (p = 0.022 FWE, SVC). Patients 
with reduced connectivity between the VL/VPL thalamus and M1/S1 and posterior insula had a 
greater reduction in pain intensity after real tDCS.  In post-hoc analyses, these changes in 
connectivity were also correlated with the change in McGill clinical pain (Table B.6). However, 
there were no significant relationships between FC and changes in positive or negative affect. In 
an analysis examining changes in connectivity and changes in clinical pain from baseline to real 
tDCS, we found that patients with reduced connectivity between left S1 and left SMA had a 
greater reduction in clinical pain (p = 0.013 FWE, Figure B.5 and Table B.5). Again, there were 
no significant relationships between increases in connectivity and decreases in clinical pain 
either between sham and real tDCS or between baseline and real tDCS (Figure B.6). 
Table 3.5. Correlations between change in FC and change in clinical pain (VAS) for real vs 
sham 
Seed 
FC Region 
MNI coordinates 
(x y z) 
r value T Cluster 
size 
Cluster p-value 
        
L VL thalamus        
R posterior insula 42 -24 20 0.887 5.08 5 0.022 FWE* 
L VPL thalamus        
L M1/S1 -48 -18 50 0.923 6.45 89 0.007 FWE* 
R posterior insula 46 -30 24 0.927 7.64 23 0.007 FWE* 
        
 
Table 3.5. Correlations between change in FC and change in clinical pain (VAS) for real vs sham. FC, functional connectivity; 
VAS, visual analog scale; L, left; R, right; VL, ventral lateral; VPL, ventral posterior lateral; M1, primary motor cortex; S1, 
primary somatosensory cortex; MNI, Montreal Neurological Institute; * = Significant at p < 0.05 with small volume correction 
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Figure 3.5. Correlation between change in FC and change in clinical pain after real tDCS. Patients with reduced FC between 
the L VPL thalamus (seed in white) and left S1/M1 and right posterior insula had greater reductions in clinical pain after real 
tDCS compared to sham (displayed at p = 0.005). VPL, ventral posterior lateral; S1, primary somatosensory cortex; M1, 
primary motor cortex; VAS, visual analog scale; L, left; R, right; FC, functional connectivity (fisher transformed r-values). 
  
Discussion 
 This study shows for the first time that a clinically relevant schedule of repetitive M1 
tDCS sessions alters FC in FM patients. Real tDCS (versus sham) reduced FC between the VL 
thalamus and SMA, mPFC, and the cerebellum. These changes in FC were distinct from those 
observed after sham tDCS.  Sham tDCS (compared to baseline) decreased connectivity between 
the VPL thalamus and S1, IPL, and the parahippocampal gyrus/amygdala and between the PAG 
and precuneus. However, after both sham and active tDCS, we found a relationship between 
decreases in FC among pro-nociceptive brain regions and reductions in clinical pain.  Patients 
with decreased connectivity between the VL thalamus and posterior insula and between the VPL 
thalamus and M1/S1 had greater reductions in clinical pain after sham and real tDCS.  In 
addition, our data indicate that FM patients with stronger baseline connectivity between left M1 
and left VL thalamus, between left S1 and left anterior insula, and between left VL thalamus and 
the PAG have a better analgesic response across the entire study. Although we see distinct main 
effects for sham and active tDCS, the overlapping results that relate to clinical changes in pain 
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may point to a shared placebo response in both sham and active conditions.  A summary of the 
results is depicted in Figure 3.6.   
	  
Figure 3.6. Summary of results. Stronger corticothalamic FC and FC between regions with high densities of opioid receptors at 
baseline predicted a better clinical response across the entire study.  Changes in FC were observed after sham tDCS, which 
could be attributed to placebo analgesia or regression to the mean. Real tDCS caused some distinct long-lasting changes in FC 
(compared to sham) and may relieve pain via the inhibition of thalamic activity and subsequent decreases in FC, both of which 
could be caused by the release of endogenous opioids. M1, primary motor cortex; S1, primary somatosensory cortex; VL, ventral 
lateral; VPL, ventral posterior lateral; Ant Ins, anterior insula; PAG, periaqueductal gray; Post Ins, posterior insula; Amyg, 
amygdala; Precun, precuneus; SMA, supplemental motor area; mPFC, medial prefrontal cortex; Cer, cerebellum; FC, 
functional connectivity. 
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Our findings are somewhat at odds with the existing literature. For example, some studies 
have reported increases in thalamic blood flow (García-Larrea et al., 1999) or increased M1 – 
thalamus connectivity after M1 stimulation (Polanía et al., 2012b; Sours et al., 2014). We 
suggest that these conflicting results can be explained by the timing of stimulation and 
measurement.  In the other studies, neural activity was measured during or immediately after M1 
stimulation, which likely has a different neural signature than after one week of repetitive 
stimulation.  In support of this notion, Garcia-Larrea and colleagues noted that 30 minutes after 
M1 stimulation stopped, thalamic blood flow reverted to baseline levels (García-Larrea et al., 
1999).  Therefore, the initial or acute changes in thalamic activity may cause a cascade of other 
events that are important for analgesia (Garcia-Larrea and Peyron, 2007), leading to the distinct 
long-term changes that we observe. 
How might M1 stimulation promote analgesia in chronic pain patients?  One hypothesis 
states that M1 stimulation suppresses pain perception directly by inhibiting activity in the lateral 
thalamus (Plow et al., 2012; Kuo et al., 2014). Compared to healthy controls, FM patients have 
increased activity in pain processing structures during experimental pain and increased 
connectivity in ascending pro-nociceptive pathways at rest (see Cagnie et al., 2014 for a recent 
review on neuroimaging findings in FM), although the specific role of the thalamus in FM 
remains unclear. Both increases and decreases in thalamic activity or connectivity during 
experimental pain or at rest have been reported (Burgmer et al., 2009; Jensen et al., 2009; Cifre 
et al., 2012; Jensen et al., 2012). In the current study, we found that strong M1 – VL thalamus 
connectivity at baseline predicted a greater reduction in pain across sham and real tDCS periods. 
This is consistent with work in central post-stroke pain where analgesic response to repetitive 
transcranial magnetic stimulation over M1 was found to be best in patients with intact 
	   78	  
thalamocortical tracts (as measured by diffusion tensor imaging) (Goto et al., 2008; Ohn et al., 
2012). Invasive motor cortex stimulation (MCS) decreases thalamic hyperactivity (Tsubokawa et 
al., 1993), likely by activating GABAergic divisions of the thalamus and increasing inhibition 
(Lucas et al., 2011).  In healthy rodents and in a rodent model of neuropathic pain, MCS 
decreases the firing rate of VPL thalamic neurons specifically (Pagano et al., 2011; 2012). In a 
previous study using the same patients reported here, we found a trend towards decreased 
glutamate + glutamine (Glx) in the bilateral thalamus after real tDCS compared to sham 
(Foerster et al., 2014). The decreases in FC between the thalamus and SMA, mPFC and 
cerebellum after real tDCS in this study lends support to the hypothesis that M1 stimulation 
disrupts thalamic activity. 
Another hypothesis is that M1 stimulation causes analgesia indirectly via the facilitation 
of descending anti-nociceptive pathways and release of endogenous opioids (Garcia-Larrea and 
Peyron, 2007).  Maarrawi and colleagues hypothesized that neuropathic pain patients with higher 
levels of endogenous opioids at baseline would be least likely to benefit from any additional 
opioid release caused by MCS, and indeed, patients with lower baseline binding potential for an 
opioid agonist (reflecting either fewer opioid receptors or higher levels of endogenous opioids) 
in the thalamus, insula and PAG were the least likely to benefit from MCS (Maarrawi et al., 
2013). The relationship between opioids and BOLD fMRI signal deserves further study, but in 
healthy controls morphine administration decreases activity in S1, thalamus and PAG (Becerra et 
al., 2006) while naloxone (an opioid antagonist) increases activity in S1, thalamus, insula and 
PAG (Borras, 2004).  In our study, stronger M1- thalamus, S1 – insula, and thalamus – PAG 
connectivity at baseline predicted a better treatment response. Since both sham and real tDCS 
also cause endogenous opioid release (DosSantos et al., 2014), this finding may suggest that 
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patients with connectivity between regions under the stimulating anode (M1/S1) and regions 
with a high density of opioid receptors are the most likely to benefit from tDCS. We also found 
decreases in FC in many of these regions after sham and real tDCS, which could also reflect 
opioid release.  
Placebo analgesia is a well-documented psychobiological event, and imaging studies 
have found overlap between brain networks involved in pain processing and those implicated in 
the placebo response (Tracey, 2010; Meissner et al., 2011). The decreases in FC found after 
sham (compared to baseline) are consistent with previous studies of placebo analgesia showing 
decreased activity in the thalamus, S1, amygdala and insula (Wager, 2004; Price et al., 2007; 
Wager et al., 2011). Importantly, the similarity of FC results related to changes in clinical pain 
between baseline and sham and between sham and real sessions may suggest a shared placebo 
component across conditions. However, the changes in FC after the sham period in this study 
cannot be interpreted solely as a placebo effect since we lacked a control group that received no 
treatment for comparison.  Therefore, any changes from baseline to sham could also reflect 
regression to the mean or the natural course of the disease (Wager and Fields, 2013). Regression 
to the mean also may account for a portion of the change in clinical pain after both the sham and 
real tDCS periods.  
Our study was limited by the small sample size, which may have contributed to the lack 
of a significant clinical effect between sham and active conditions and reduced statistical power.  
This pilot study did not aim to validate the efficacy of M1 tDCS as a treatment for FM; rather 
our goal was to determine if a clinically relevant schedule of tDCS sessions altered resting state 
FC in FM patients. However, as with most pain treatments wherein only a portion have a 
clinically meaningful response, half of the patients in this study did report a drop in pain on the 
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VAS (active – sham), and this change was correlated with reductions in thalamo-cortical 
connectivity.  This study is significantly limited by the lack of counterbalancing between sham 
and active conditions. Therefore, we cannot rule out carry-over effects from the sham period.  
However, sham and active phases were separated by a wash out period of at least one week, so 
we find this unlikely. Another limitation is that the stimulation sessions were single blinded. 
Finally, research has shown that stimulating for 30 seconds at the beginning and end of the sham 
condition can mimic the sensation during active treatment and that patients can not differentiate 
between sham and real at 1 mA (Gandiga et al., 2006). However, the credibility of sham tDCS 
and the effectiveness of patient blinding at 2 mA has recently been questioned (O'Connell et al., 
2014). Given our repeated measures design, it is likely that the patients became aware of the 
condition differences. Our results should be interpreted with caution and additional studies will 
be needed to replicate our findings.  
Conclusion 
Our results support the hypothesis that repetitive M1 tDCS causes lasting changes in FC and may 
relieve pain by altering thalamic activity. Analgesia may result from the inhibition of thalamic 
activity and subsequent decreases in FC, both of which could be caused by the release of 
endogenous opioids. Future studies that combine fMRI and PET within the same patients after 
repetitive M1 tDCS are needed to test this hypothesis. It is possible that there is a significant 
placebo component common to both sham and real tDCS. Future studies should include a no-
treatment control group to test this hypothesis. It remains to be seen if similar changes in FC are 
observed for tDCS in other chronic pain conditions.   
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Chapter 4 : Conclusions and Future Directions 
This dissertation investigated alterations in functional brain network hubs in FM and how 
non-invasive brain stimulation can alter brain network connectivity to produce analgesia in these 
patients.  The main contributions of this research are a better understanding of how functional 
hubs, the regions most fundamental to efficiency and information transfer in the brain, are 
reorganized in FM and how increases in an excitatory neurotransmitter may influence hub status 
and lead to increases in clinical pain.  Further, this dissertation adds to the knowledge of how a 
clinically relevant schedule of M1 tDCS treatment alters brain connectivity to cause analgesia.  
By identifying brain network alterations present in an individual patient, combined with the 
analgesic mechanism of action of noninvasive brain stimulation at a particular site, treatment 
may be personalized to the type of central alteration present in each patient. 
Summary of Findings 
In Chapter 2, we applied a brain network based approach to examine hub topology in 
FM. Resting state functional MRI data from 40 FM patients and 27 healthy volunteers were 
analyzed using graph theoretical techniques. We also measured the concentration of Glx in the 
right posterior insula using 1H-MRS in each participant. We identified significant disruptions in 
hub rank order in FM patients as compared to healthy volunteers. In general, brain regions that 
were hubs in FM patients, such as the superior temporal gyrus, mid and anterior insula, were 
non-hubs with low degree or centrality in healthy controls.  Conversely, hubs in healthy controls, 
such as primary and secondary visual cortices and superior frontal gyrus, were non-hubs in FM.  
In FM, but not controls, the anterior insula was a connector hub with significantly higher inter-
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modular connectivity.  Both FM and healthy control networks had a rich club organization, 
however the membership of hubs within the rich club was different between groups.  In FM, the 
bilateral anterior insulae was a member of the rich club and the visual network was integrated 
with the rest of the rich club.  In healthy volunteers, the visual network was segregated into its 
own module distinct from other rich club nodes.  
Among FM patients, rich club membership varied with the intensity of clinical pain: the 
posterior insula as well as M1 and S1 belonged to the rich club only in FM patients with the 
highest pain levels.  The rich club in the low pain FM group more closely resembled that of 
healthy controls.  Further, we found that the eigenvector centrality (a measure of how connected 
a brain region is to other highly connected regions) of two nodes in the posterior insula and 14 
bilateral M1 and S1 nodes positively correlated with clinical pain.  The two posterior insula 
nodes overlapped with the spectroscopic voxel where we measured each participant’s level of 
Glx. We demonstrated that eigenvector centrality in the posterior insula mediated the 
relationship between levels of Glx within this structure and the patient’s clinical pain report.  
These data are consistent with preclinical findings in rodents wherein increasing endogenous 
levels of glutamate in the insula led to increases in hyperalgesia and allodynia (Watson, 2016).  
Taken together, these findings demonstrate an altered hub topology in the chronic pain 
state of FM and suggest that, within the chronic pain network, pro-nociceptive regions (such as 
the insulae) appear to have acquired hub status that would redefine information processing and 
integration for the network.  Moreover, the intensity of chronic pain may be related to the 
composition of hubs in the rich club.  Finally, these data are the first to suggest that disruptions 
in the excitatory tone within the insula could alter the strength of the insula as a hub and 
subsequently lead to increased clinical pain.  
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In Chapter 3, we had three goals: first, determine if functional connectivity at baseline 
can predict treatment response to M1 tDCS in FM patients.  Second, examine if and how 
functional connectivity changes after the treatment, and third, assess if these changes relate to 
analgesia.  Twelve FM patients underwent a resting state functional connectivity fMRI scan at 
baseline, after five days of sham tDCS and after 5 days of real M1 tDCS.  Clinical pain intensity 
was measured at all three time points.  Stronger baseline functional connectivity between M1 
(under the stimulating anode) and the ventral lateral thalamus, S1 to the anterior insula, and 
ventral lateral thalamus to the PAG predicted greater analgesia after sham and real tDCS.  These 
findings are consistent with data from invasive motor cortex stimulation wherein patients with 
intact thalamocortical tracts have the best analgesic response (Goto et al., 2008; Ohn et al., 
2012).  Additionally, since M1 tDCS may act via the endogenous opioid system (DosSantos et 
al., 2012), our findings also suggest that patients who have strong connectivity between regions 
under the stimulating anode and regions with a high density of opioid receptors may be most 
likely to benefit from this treatment.   
Both sham and real tDCS caused reductions in functional connectivity.  Sham tDCS 
(compared to baseline) reduced functional connectivity between the ventral posterior lateral 
thalamus, S1 and the amygdala, findings which are consistent with neural responses during 
placebo analgesia (Wager, 2004; Price et al., 2007; Wager et al., 2011).  Real tDCS (compared to 
sham) reduced functional connectivity between the ventral lateral thalamus, medial prefrontal 
and supplementary motor cortices. Interestingly, decreased functional connectivity between the 
ventral lateral/ventral posterior lateral thalamus and posterior insula, M1 and S1 correlated with 
reductions in clinical pain after both sham and active treatment. In total, these results suggest that 
while there may be a placebo response common to both sham and real tDCS, repetitive M1 tDCS 
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causes distinct changes in functional connectivity that last beyond the stimulation period. The 
majority of the findings we report in Chapter 3 center on reductions in connectivity between the 
thalamus and other cortical regions.  This lends support to the hypothesis that the analgesic 
actions M1 tDCS may stem from reductions in pro-nociceptive thalamic hyperactivity (Kuo et 
al., 2014).   
Implications and Conclusions   
The Motor Cortex Plays a Role in Pain Perception 
The primary motor cortex (M1) is not classically defined as a member of the ‘pain 
matrix’, although its role in chronic pain is beginning to be examined. M1 shares many 
connections with the sensory nuclei of the thalamus and other pain processing regions and may 
therefore be an important modulator of pain perception by virtue of its connectivity patterns 
(Saavedra et al., 2014). M1 stimulation with tDCS increases pain and sensory thresholds in 
healthy volunteers (Reidler et al., 2012; Vaseghi et al., 2014) and causes lasting clinical pain 
reduction in FM (Fregni et al., 2006; Valle et al., 2009; Fagerlund et al., 2015).   
However, in FM patients, motor cortex excitability at baseline and in response to sensory 
stimuli is abnormally increased (Mhalla:2010iy; Cook et al., 2004). We found that the bilateral 
M1 were hubs and members of the rich club in the FM patients with the highest intensity of 
clinical pain.  Additionally, as measured with eigenvector centrality, the more connected M1 was 
to other high degree nodes, then the greater the clinical pain rating.  If we conclude from these 
data that M1 is a hyperactive hub in FM, then why would anodal stimulation of M1, presumably 
an excitatory intervention, lead to reductions in functional connectivity and analgesia?  
The most common way to measure the effect of M1 tDCS on cortical excitability is to 
measure motor evoked potentials. Anodal stimulation increases the amplitude of motor evoked 
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potentials, while cathodal stimulation decreases it (Nitsche and Paulus, 2000).  These results 
have led to the convenient interpretation that anodal tDCS is excitatory and cathodal tDCS is 
inhibitory, although this may not be true in all circumstances.  Antal and colleagues found that 
when healthy subjects are simultaneously given anodal M1 tDCS and performing a motor task 
that presumably activates M1, the motor evoked potential amplitude is lower compared to anodal 
M1 stimulation given while participants were at rest (Antal et al., 2007).  These results suggest 
that tDCS-induced plasticity may be dependent on the baseline state of the targeted brain region.  
According to the Bienenstock-Cooper-Munro (BCM) model of plasticity, synaptic potentiation is 
more likely to occur if postsynaptic activity is low.  Synaptic depression, on the other hand, is 
more likely to occur if postsynaptic activity is high (Bienenstock et al., 1982) (see (Lefaucheur et 
al., 2017) for a discussion of this model in the context of noninvasive brain stimulation).  This 
model may explain why changes in cortical excitability after tDCS depend on whether the 
participant is at rest or performing a task that engages the area being targeted.  In the case of our 
findings, if M1 is active at rest (as one might conclude from our results that show M1 has many 
more connections at rest in a patient with high pain compared to low pain), then anodal M1 tDCS 
might act in an inhibitory manner.  Therefore, M1 tDCS might be causing analgesia in some 
patients by decreasing the hub status of M1 regions – a hypothesis that is supported by our 
findings in Chapter 3 where anodal M1 tDCS caused reductions in functional connectivity 
between M1, S1 and other cortical regions.     
The Insular Cortex may be a “Pain Hub” and a Target of M1 tDCS 
The insula is highly connected to the rest of the brain, which may explain why it is 
implicated is so many functions, including somatosensory, autonomic, interoception, salience 
detection and cognitive processes (Borsook et al., 2016). One general hypothesis is that the 
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insula performs a role in converting salient physiological inputs into higher level cognitive states 
or emotions (Borsook et al., 2016). There is evidence that the anterior insula acts as in a causal 
manner to coordinate and change brain dynamics in many large scale networks (Uddin, 2015).  
The insula’s role as a sensory integration region that is critical for pain perception is supported 
by studies in which direct electrical stimulation of the posterior insula elicited painful sensations 
(Ostrowsky et al., 2002; Mazzola et al., 2009) and insular lesions alter pain perception (Garcia-
Larrea and Peyron, 2013).  Activity in the posterior insula also tracked over time with 
experimental heat pain intensity ratings (Segerdahl et al., 2015).  
In the first study of this dissertation, we found that the anterior insula was a hub, and had 
many connections to brain regions outside its own functional system in FM patients but not 
healthy controls.  This region was also a member of the rich club – the functional backbone of 
connectivity that influences information integration across the whole brain network.  In FM 
patients with the highest pain, this was also true for the posterior insula.  In the second study of 
this dissertation, we showed that FM patients who experienced the greatest analgesic effect after 
M1 tDCS also had reductions in functional connectivity between the ventral lateral/ventral 
posterior lateral thalamus and the posterior insula.  This finding met our criteria for statistical 
significance, however, we did observe other reductions in functional connectivity after M1 tDCS 
between the anterior and posterior insula and other cortical regions, some of which also 
correlated with analgesia.  These observations were not reported in Chapter 3 because they were 
not significant after correcting for multiple comparisons.  It is possible that the sample size 
(n=12) was too small to detect significant decreases in connectivity in the insula.  Another 
possibility is that the graph theoretical measures used in Chapter 2 would have detected a change 
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in insular hub status after tDCS.  This should be investigated in future studies with a larger 
number of patients.    
Glutamate and GABA Influence Pain Perception and are Altered by M1 tDCS 
Patients with FM have elevated levels of Glx in the posterior insula compared to healthy 
volunteers (Harris et al., 2009).  Moreover, higher Glx is associated with lower experimental 
pain thresholds in these patients.  After a non-pharmacological treatment, the FM patients with 
reductions in Glx within the posterior insula also experience decreases in clinical pain and 
sensitivity to experimental pain stimuli (Harris et al., 2008).  Similarly, an effective 
pharmacological analgesic treatment reduced insular Glx in FM (Harris et al., 2013).  FM 
patients also have lower GABA concentrations in the anterior insula relative to healthy controls, 
and patients with lower GABA levels in the posterior insula were more sensitive to experimental 
pressure pain (Foerster et al., 2012).  Alterations in the excitatory-inhibitory balance in the insula 
have also been found in other chronic pain conditions (Petrou et al., 2012; As-Sanie et al., 2016).  
In Chapter 2 we found that the high pain FM group had significantly higher 
concentrations of Glx in the posterior insula compared to the low pain FM group.  There were 
two nodes in the posterior insula that overlapped with the spectroscopic voxel; hence, we sought 
to examine the relationship between graph theoretical measures, Glx and clinical pain in FM 
patients.  We demonstrated that the eigenvector centrality of posterior insula nodes mediated the 
relationship between Glx and clinical pain.  These data are consistent with a recent preclinical 
study wherein either increasing glutamate or decreasing GABA led to increased hyperalgesia and 
allodynia in naïve rats (Watson, 2016).  Further, rats with a chronic constriction injury to the 
sciatic nerve, a rodent model for chronic neuropathic pain, had higher glutamate levels in the 
insula compared to controls.  Following a microinjection of a glutamate receptor antagonist or 
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GABA into the insular region, the nociceptive behaviors in the injured rats decreased.  Together, 
these data indicate that the excitatory-inhibitory balance in the insula exerts a causal influence on 
pain perception. 
In addition to the functional connectivity changes after M1 tDCS that we report in 
Chapter 3, our laboratory previously examined changes in excitatory and inhibitory 
neurotransmitters after treatment in the same FM patients studied here (Foerster et al., 2014).  
We found that five days of M1 tDCS treatment significantly decreased Glx in the ACC 
compared to sham.  There was a trend towards decreased Glx in the bilateral thalami after M1 
tDCS compared to sham, although this did not meet statistical significance.  Finally, M1 tDCS 
increased GABA in the anterior insula relative to the baseline scan (Foerster et al., 2014).  The 
authors did not find any significant changes in anterior insula Glx, or posterior insula Glx or 
GABA. It is possible that the study was underpowered (n=12) to detect changes in posterior 
insula neurochemistry.  
Taken together, it is clear that glutamate and GABA in the insula impact pain perception 
and are altered in chronic pain.  Therefore, treatments that decrease glutamate and/or increase 
GABA in the insula may be effective analgesics in some patients.  Our conclusion from these 
data is that molecular alterations of the excitatory tone of the insula can impact the functionally 
derived hub status of this region and lead to subsequent changes in the clinical pain percept.  
Future tDCS studies with a larger number of participants should confirm the impact of M1 
stimulation on insular Glx and GABA.  If the null results are confirmed, other tDCS targets that 
may change the excitatory-inhibitory tone in the insula should be explored.  
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Future Directions  
Biomarkers for Chronic Pain 
A biomarker is broadly defined as a biochemical, physiological or anatomical trait that 
reliably predicts a biological state (Fidalgo et al., 2014).  Ideally, biomarkers should identify or 
predict individuals with a disease and they should change with successful treatment.  In chronic 
pain, biomarkers would be helpful to patients who desire validation of an oftentimes invisible 
condition, and useful for researchers and clinicians to obtain additional information about the 
status or trajectory of a disease beyond the patient self-report (Davis et al., 2017).  Neuroimaging 
has the potential to generate biomarkers based on brain activity related to pain perception, 
although this goal should be pursued with care (see Davis et al., 2017 for an extensive discussion 
of the ethics and challenges of developing biomarkers for chronic pain). Multivariate pattern 
analysis and machine learning have been used to identify patterns in neuroimaging data that are 
predictive of pain or disease status (Wager et al., 2013; Ung et al., 2014; López-Solà et al., 
2016).  Network topology and functional connectivity (as examined in this dissertation) also 
have the potential to serve as biomarkers for chronic pain.  Future studies should replicate our 
findings in Chapter 2 and determine if the hub status of insular, M1 and S1 regions track with 
changes in clinical pain over time or decrease with successful treatment.  It also remains unclear 
if our findings translate into other chronic centralized pain conditions.  Larger studies with 
diverse individuals (age, sex, race, ethnicity) and different chronic pain conditions are warranted.  
Personalized Treatment  
Given the many legal and ethical challenges of chronic pain biomarkers (Davis et al., 
2017), it is our conclusion that the best use of a brain biomarker would be to optimize treatment 
by tailoring interventions based on an individual patient’s neurobiology.  Despite its clinical 
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promise, tDCS still faces many engineering and research challenges, such as the fine-tuning of 
stimulation parameters (intensity, duration of stimulation, number of treatments required, etc.) 
and the delineation of which brain regions should be targeted to produce the maximum treatment 
benefit.  Biomarkers may serve as a guidepost for new targets in noninvasive brain stimulation 
research and clinical trials (Fidalgo et al., 2014). 
There are many ways in which tDCS could be personalized to an individual patient.  The 
histology of brain regions varies between individuals and, therefore, applying stimulation based 
on group-average coordinates is not the best approach.  Structural MRI data can be used to 
determine the shape and position of the stimulating electrode with more precision than a group 
average placement. Computational modeling has shown that this approach can lead to stronger 
current in the targeted brain regions (Cancelli et al., 2015b).  M1 cortical excitability (measured 
using hand motor evoked potentials) was higher using a personalized electrode compared to non-
personalized fit based on the standard electroencephalography 10-20 International system as 
typically done (Cancelli et al., 2015a). This approach was recently used clinically to reduce 
fatigue in multiple sclerosis (Cancelli et al., 2017).   
Structural and functional connectivity could also be used to determine the best 
stimulation target. For example, participants with stronger dorsolateral prefrontal cortex 
(DLPFC) – thalamus structural connectivity experienced more pain relief during anodal DLPFC 
stimulation (presumably via a top-down activation of descending analgesic pathways from the 
DLPFC to the PAG that pass through the thalamus) (Lin et al., 2017).  The structural 
connectivity also related to the functional connectivity between these two regions.  The 
functional connectivity profile of the DLPFC is more similar within an individual subject on 
different days than to an average population map (Fox et al., 2013). Fox et al. identified regions 
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of the DLPFC that produced a more effective antidepressant response when stimulated compared 
to other DLPFC sites and that this difference related to functional connectivity (Fox et al., 2012).  
Effective sites had strong anti-correlated connectivity between that region and the subgenual 
ACC.  The specific region of the DLPFC with the strongest anti-correlation to the ACC varied 
between patients.  In another example, corticostriatal connectivity predicted treatment response 
to dorsomedial prefrontal cortex transcranial magnetic stimulation (Dunlop et al., 2016). In this 
case, the non-responders (50%) had less corticostriatal connectivity at baseline compared to 
responders.  Treatment responses may depend on structural and functional brain circuitry and 
may help explain the wide variances of clinical outcomes after tDCS treatment. By using 
connectivity at baseline to guide treatment, some of this variance may be reduced.  
The findings of this dissertation suggest that anodal M1 tDCS may be most effective in 
alleviating pain in those FM patients where the insula, M1 and S1 are acting as highly connected 
hub regions in the brain network.  More specifically, patients with high M1-thalamus-PAG 
connectivity at baseline might respond best to M1 tDCS.  For patients with a different hub 
topology or connectivity pattern, an alternative stimulation site may produce better results. We 
would predict that patients with stronger DLPFC – thalamus – PAG connectivity would be better 
candidates for tDCS targeted to the DLPFC.  These possibilities should be examined in future 
studies.   
Developing New Targets for tDCS Treatment of Chronic Pain 
As we have outlined above, M1 stimulation may not be the best treatment approach in all 
chronic pain patients.  New targets for brain stimulation should be explored and the research 
presented in this dissertation suggests that targeting hub brain regions for a tDCS “attack” (i.e. 
decreasing or reorganizing the hub structure in chronic pain patients) could be a successful 
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treatment approach.  Graph theoretical analyses applied to computer simulations of human brain 
networks have the potential to model the consequences of targeting a novel region without the 
expense or risk of human trials (Medaglia, 2017).   
A recent study used network control theory to predict the effects of stimulating different 
brain regions using a computational model of a structural brain network (Muldoon et al., 2016).  
In this context, ‘control’ refers to the ability to manipulate local activity in order to drive the 
global network towards a desired state.  Regions with high degree (strongly connected hubs) had 
the highest average controllability, while brain regions with few connections had low 
controllability. Stimulating brain regions with high controllability resulted in the large changes to 
the functional state of the brain network (measured as the change in functional connectivity in 
the computational model after stimulation), and the amount of this global activation was 
unconstrained by the underlying structural connectivity.  On the other hand, stimulating regions 
with low controllability led to focal activation only, and this activation was constrained and 
predicted by structural connectivity.  In general, based on a model using structural brain data 
from healthy volunteers, regions of the medial DMN had high controllability and produced large 
functional effects on the rest of the brain network when stimulated. The postcentral gyrus (S1) 
had medium controllability and stimulating this region led to moderate changes in functional 
connectivity across the whole brain network. The results of this study suggest two classes of 
therapeutic interventions: a ‘broad reset’ where stimulating a highly connected hub leads to 
widespread activation and alteration of global brain dynamics, and ‘focal’ targeting wherein 
stimulating sparsely connected regions alters the functional dynamics of relatively few areas.  
The controllability measure could be used to predict network-wide effects of stimulation on a 
specific brain region.  Applying these principles to our data, we would predict that hubs in FM 
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(anterior insula in all patients; S1, M1 and posterior insula in high pain patients) would have high 
controllability and stimulation would lead to large effects on global network dynamics.  
Conversely, stimulating non-hubs (visual cortex) would produce focal changes in connectivity.  
As we discuss in Chapter 1, the CNS alterations observed in FM are not limited to any one brain 
region or pathway.  Therefore, future tDCS studies should examine the analgesic effects of 
targeting hub brain regions.    
Concluding Remarks 
Chronic pain is an enormous personal, societal and economic burden.  Individuals who 
suffer from a chronic widespread pain have a reduced quality of life and excess mortality rates 
(Clauw, 2014; Macfarlane et al., 2017). Chronic pain is a leading cause of disability and costs for 
medical treatment and lost productivity exceed $550 billion annually in the United States 
(Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education, 
2011).  
Simultaneously, the United States is in the midst of an opioid epidemic.  In 2015, there 
were 33,091 deaths due to an opioid overdose (Rudd et al., 2016), and most of these individuals 
first encountered an opioid for the management of acute or chronic pain (Schneiderhan et al., 
2017).  Paradoxically, there is no evidence that opioids effectively treat chronic pain and may 
instead lead to poorer long-term outcomes (Brummett et al., 2015; Goldenberg et al., 2016).  In 
the United States, there are three drugs currently approved by the US Food and Drug 
Administration (FDA) for the treatment of FM. However, only 30-40% of patients experience a 
meaningful reduction in pain while taking these drugs and there are substantial side effects (see 
(Häuser et al., 2014)for a review on the efficacy of pharmacological therapies). Noninvasive 
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brain stimulation has emerged as a potential treatment for chronic centralized pain conditions, 
although the outcomes of clinical trials have been mixed (O'Connell et al., 2014).   
This research offers new insight into the neurobiology of chronic centralized pain 
conditions, identifies a candidate diagnostic marker of chronic pain, and may contribute to the 
understanding of how non-invasive brain stimulation treatments cause analgesia. This knowledge 
could lead to more informed stimulation sites and personalized treatment based on brain network 
organization and connectivity in an individual patient.  Longitudinal studies are needed to 
determine causality and to measure if network organization changes with successful treatment. 
Future studies should also examine the effect on brain network connectivity at other stimulation 
sites.  
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Appendix A : Supplementary Figures and Tables 
	  
Figure A.1. Right Posterior Insula 1H-MRS Voxel Placement and Resulting Spectrum. The placement of the spectroscopic voxel 
in the right posterior insula is shown in (A) in axial, coronal and sagittal images.  A representative spectrum fit with LCModel 
(red trace) is depicted in panel (B). The peak resonance for glutamate + glutamine (Glx) is marked with * at 2.35 parts per 
million. Glx concentrations were rescaled using the water peak and corrected for CSF. 
Table A.1: No Significant Differences in Grey/White Matter or CSF Volume in the 1H-
MRS Voxel between FM and HC 
 
 
 
 
 
 
 
 
Right Posterior 
Insula 1H-MRS 
Voxel 
FM(mean ± SD) HC (mean ± SD) Statistics 
Grey Matter 0.3390 ± 0.08 0.3259 ± 0.08 t=-0.641, p=0.524 
White Matter 0.6196 ± 0.09 0.6334 ± 0.08 t=0.591, p=0.557 
CSF 0.0394 ± 0.02 0.0391 ± 0.01 t=-0.065,p=0.948 
Table A.1. No Significant Differences in Grey/White Matter or CSF Volume in the 1H-MRS Voxel between FM and HC. FM, 
fibromyalgia; HC, healthy control; SD, standard deviation; 1H-MRS, proton magnetic resonance spectroscopy 
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Table A.2: No Significant Differences in Grey/White Matter or CSF Volume of the 1H-
MRS Voxel between FM Pain Tertiles 
 
 
 
Table A.3: Participant Demographics 
 
 FM (n=40, unless 
otherwise noted) 
HC (n=27, unless 
otherwise noted) 
Statistics 
Age (mean ± SD) 39.03 ± 11.04 36.22 ± 12.43 t = 0.969, p = 0.336 
Race 92.5% Caucasian, 5% 
African American, 2.5% 
Other  
N = 15; 80% Caucasian, 
7% Indian, 13% Asian 
 
Ethnicity N = 30; 97% Non-
Hispanic White, 3% 
Hispanic 
N = 15; 93% Non-
Hispanic 7% Hispanic 
 
Posterior insula Glx 
CSF corrected (mean ± 
SD AIU) 
N = 39; 11.92 ± 1.57 10.97 ± 1.48 t = 2.45, p = 0.017 
Posterior insula Glx 
ratio to total creatine 
(mean ± SD AIU) 
N = 37; 1.62 ± 0.17 N = 25; 1.63 ± 0.21 t = 0.269, p = 0.789 
Clinical Pain (VAS: 
mean ± SD) 
4.88 ± 2.24   
Depression (HADS: 
mean ± SD)  
N = 18; 5.11 ± 3.54   
Depression (CES-D: 
mean ± SD) 
N = 12; 14.75 ± 7.55   
 
Table A.3. Participant Demographics. FM, fibromyalgia; HC, healthy control; SD, standard deviation; Glx, glutamate + 
glutamine; AIU, arbitrary institutional units; VAS, visual analog scale; HADS, Hospital Anxiety and Depression scale; CES-D, 
Center for Epidemiological Studies-Depression Scale  
 
 
 
 
 
 
 
 
 
 
 
 
Table A.2. No Significant Differences in Grey/White Matter or CSF Volume of the 1H-MRS Voxel between FM Pain Tertiles. FM, 
fibromyalgia; SD, standard deviation; 1H-MRS, proton magnetic resonance spectroscopy  
Right Posterior 
Insula 1H-MRS 
Voxel 
High Pain FM (mean ± 
SD) 
Medium Pain FM 
(mean ± SD) 
Low Pain FM 
(mean ± SD) 
Statistics 
Grey Matter 0.3259 ± 0.08 0.3605 ± 0.09 0.3441 ± 0.08 F=1.208, p=0.314 
White Matter 0.6333 ± 0.10 0.5968 ± 0.10 0.6112 ± 0.08 F=1.188, p=0.321 
CSF 0.0391 ± 0.02 0.0401 ± 0.02 0.0429 ± 0.01 F=0.454,p=0.715 
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Table A.4: Current Medications in Fibromyalgia Patients 
 
Medication # Fibromyalgia Patients  
Antidepressants (SSNRI, SSRI, NDRI, TCA) 9 
Benzodiazepines  3 
Pregabalin 2 
Opioids/Narcotic Analgesics 5 
Muscle Relaxants 8 
NSAIDs 20 
Marijuana 1 
 
Table A.4. Current Medications in Fibromyalgia Patients. Data not collected in 9 FM participants, table above contains 
medication usage for remaining n=31 FM patients 
	  
 
Table A.5: Global Network Measures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Measure FM(mean ± SD) HC (mean ± SD) Statistics 
Global 
Efficiency 
0.5740 ± 0.005 0.5733 ± 0.007 t=0.419, p=0.657 
Clustering 
Coefficient 
0.4730 ± 0.025 0.4739 ± 0.033 t=0.109, p=0.899 
Average Path 
Length 
2.01 ± 0.03 2.02 ± 0.05 t=0.694,p=0.490 
Modularity 0.3349 ± 0.027 0.3406 ± 0.033 t=0.750, p=0.439 
 
Table A.5. Global Network Measures. FM, fibromyalgia; HC, healthy control; SD, standard deviation 
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Table A.6: Hubs (Degree) in Fibromyalgia Patients and Healthy Controls 
 
Hubs in Fibromyalgia Patients 
Brain Region (Node #) Degree 
Hubs in Healthy Controls 
Brain Region (Node #) Degree 
L Inferior Frontal Gyrus (242) 66.8 R Inferior Parietal Lobule (192) 66.5 
Dorsal Anterior Cingulate (215) 67.2 L Superior Frontal Gyrus (218) 66.5 
R Precuneus (156) 67.6 R Supplementary Motor Area (16) 66.5 
L Mid Insula/Operculum (55) 67.8 R Precuneus (136) 66.6 
R Superior Parietal (258) 68.1 R Primary/Secondary Visual Cortex (140) 66.8 
L Primary Somatosensory Cortex (69) 68.2 L Superior Frontal Gyrus (50) 66.8 
R Inferior Temporal Gyrus (179) 68.5 L Primary Somatosensory Cortex (23) 67.2 
R Superior Temporal Gyrus (240) 68.5 L Primary Somatosensory Cortex (69) 67.2 
R Mid Frontal Gyrus (189) 68.7 L Primary/Secondary Visual Cortex (154) 67.3 
R Mid Cingulate (216) 68.8 R Visual Association Cortex (169) 67.5 
L Mid Cingulate (94) 68.9 R Supplementary Motor Area (53) 67.5 
L Precuneus (166) 69.1 L Inferior Frontal Gyrus (242) 67.7 
R Mid Insula (60) 69.5 L Inferior Parietal Lobule (177) 67.7 
R Inferior Frontal Gyrus (186) 69.5 R Angular Gyrus (96) 68.6 
R Superior Temporal Gyrus (63) 69.7 R Supplementary Motor Area (54) 68.7 
R Precuneus (136) 69.7 R Primary Motor Cortex (29) 68.8 
L Primary Motor Cortex/Operculum (70) 69.8 R Superior Frontal Gyrus (219) 69.1 
R Anterior Insula (209) 70.2 R Posterior Cingulate (203) 69.1 
L Anterior Insula (208) 70.5 R Superior Temporal Gyrus (62) 69.3 
R Primary Motor Cortex (29) 70.5 L Mid Temporal Gyrus (83) 69.4 
R Supramarginal Gyrus (204) 70.7 L Superior Temporal Gyrus (58) 69.4 
R Supplementary Motor Area (54) 70.8 R Mid Cingulate (216) 69.7 
L Primary Somatosensory Cortex (65) 70.9 R Mid Insula (56) 70.4 
R Posterior Cingulate (203) 71.4 L Mid Cingulate (59) 70.4 
L Mid Cingulate (59) 71.9 R supramarginal gyrus (204) 70.9 
L Inferior Parietal Lobule (235) 72.5 L Primary Somatosensory Cortex (65) 71.0 
L Mid Cingulate (213) 72.8 R Primary Visual Cortex (141) 71.6 
L Supplementary Motor Area (47) 74.1 R Secondary Visual Cortex (165) 72.6 
R Superior Temporal Gyrus (62) 75.5 L Primary/Secondary Visual Cortex (172) 72.7 
L Supplementary Motor Area (15) 76.4 R Visual Association Cortex (153) 72.7 
R Mid Insula (56) 77.2 L Mid Cingulate (213) 72.8 
L Superior Temporal Gyrus (58) 77.6 L Supplementary Motor Area (47) 73.3 
  L Supplementary Motor Area (15) 74.3 
 
Table A.6. Hubs (Degree) in Fibromyalgia Patients and Healthy Controls. L, left; R, right. 
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Table A.7: Hubs (Betweenness Centrality) in Fibromyalgia Patients and Healthy Controls 
 
Hubs in Fibromyalgia Patients 
Brain Region (Node #) 
Betweenness 
Centrality 
Hubs in Healthy Controls 
Brain Region (Node #) 
Betweenness 
Centrality 
R Mid Insula (60) 328.8 R Primary Visual Cortex (141) 328.7 
L Primary Motor/Operculum (70) 329.3 R Superior Temporal Gyrus (62) 329.1 
R Superior Parietal (258) 330.3 R Superior Temporal Gyrus (63) 329.6 
R Anterior Insula (211) 331.1 L Superior Frontal Gyrus (178) 335.1 
R Inferior Frontal Gyrus (139) 332.6 L Superior Frontal Gyrus (220) 335.4 
L Superior Temporal Gyrus (236) 333.2 R Precuneus (156) 337.8 
L Inferior Frontal Gyrus (137) 333.6 R Inferior Frontal Gyrus (139) 339.1 
R Mid Temporal Gyrus (119) 333.7 R Inferior Parietal Lobule (190) 339.3 
R Precuneus (156) 338.8 R Mid Frontal Gyrus (189) 341.9 
R Superior Temporal Gyrus (63) 341.1 L Superior Frontal Gyrus (103) 342.9 
R Precuneus (251) 344.1 R Angular (96) 345.7 
R Mid Frontal Gyrus (189) 345.4 L Inferior Parietal Lobule (177) 346.0 
R Cuneus (159) 346.1 L Inferior Frontal Gyrus (176) 351.0 
L Anterior Insula (208) 347.5 R Visual Association Cortex (153) 351.4 
R Mid Cingulate (216) 347.8 R Inferior Parietal Lobule (192) 354.2 
L Superior Frontal Gyrus (112) 349.8 L Mid Temporal Gyrus (120) 356.4 
L Angular Gyrus (87) 351.4 R Primary Motor Cortex (29) 359.7 
R Inferior Frontal Gyrus (186) 352.7 R Precuneus (163) 362.7 
L Primary Somatosensory Cortex (65) 354.5 R Cuneus (159) 365.5 
R Superior Temporal Gyrus (240) 355.9 L Precuneus (13) 367.3 
L Inferior Frontal Gyrus (176) 356.6 L Mid Cingulate (59) 368.2 
Dorsal Anterior Cingulate (215) 357.2 R Secondary Visual Cortex (165) 370.2 
R Precuneus (136) 358.8 Dorsal Anterior Cingulate (215) 370.8 
L Superior Frontal Gyrus (202) 372.2 L Secondary/Association Visual Cortex (172) 371.2 
L Mid Cingulate (59) 377.6 L Mid Cingulate (94) 372.4 
R Posterior Cingulate (203) 377.8 R Mid Cingulate (216) 372.9 
R Inferior Temporal Gyrus (179) 377.9 L Supplementary Motor Area (47) 375.4 
R Precuneus (163) 381.7 L Supplementary Motor Area (138) 376.3 
R Inferior Parietal Lobule (235) 382.2 L Inferior Frontal Gyrus (242) 382.8 
R Supramarginal Gyrus (204) 383.6 R Mid Insula (56) 388.7 
L Supplementary Motor Area (47) 386.4 L Superior Temporal Gyrus (58) 390.7 
L Mid Cingulate (213) 387.7 R Superior Frontal Gyrus (219) 393.1 
R Primary Motor Cortex (29) 392.4 R Posterior Cingulate (203) 394.5 
L Mid Cingulate (94) 399.5 L Medial Superior Frontal Gyrus (202) 397.6 
R Superior Temporal Gyrus (62) 401.3 R Precuneus (136) 412.9 
L Inferior Frontal Gyrus (242) 408.1 L Mid Cingulate (213) 419.2 
L Superior Temporal Gyrus (58) 458.6 R Supramarginal (204) 424.6 
L Supplementary Motor Area (15) 473.4 L Supplementary Motor Area (15) 438.0 
R Mid Insula (56) 477.9   
Table A.7. Hubs (Betweenness Centrality) in Fibromyalgia Patients and Healthy Controls. L, left; R, right. 
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Figure A.2. Rich Club Membership across thresholds in FM and HC.  Rich club membership is depicted for FM and HC at each 
of the thresholds examined, 10-40% (A-G). As described in the main text, we determined statistical significance of the rich club 
coefficient, ϕ (k), at each level of k with permutation testing using 1000 random networks with similar degree distribution and 
density. The range of k in which ϕ (k) is significantly different from ϕ random (k), and where the ϕ norm (k) is greater than one, is the 
rich-club regime. Differences between FM and HC in ϕ (k) at each level of k in the rich-club regime were tested in SPSS using 
independent samples t-tests. This was repeated for each threshold and a Bonferroni correction was applied. There were no 
significant differences in the rich club coefficient between FM and HC, however rich club membership was different between 
groups.  The anterior insulae was a member of the rich club in FM patients for network densities between 20 and 40%. For 
visualization, the rich clubs are displayed at the highest level of k that was significantly different from random networks for each 
threshold and each group independently (10%: FM k= 47, HC k = 45; 15%: FM k = 64, HC k = 62; 20%: FM k = 78, HC k = 
82; 25%: FM k = 92, HC k = 95; 30%: FM k = 106, HC k = 111; 35%: FM k = 121, HC k = 126; 40%: FM k = 133, HC k = 
142). 
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Figure A.3. Rich Club Hubs in FM Tertiles across thresholds.   For high, medium and low pain FM tertiles, the rich club 
membership is depicted for all other network densities examined (10-40%, A-G). Differences in the rich club coefficient, ϕ (k), for 
each threshold were tested as described in the main text using one-way ANOVAs and Bonferroni corrections were applied.  
There were no significant differences between the tertiles in the rich club coefficient, however rich club membership varied 
across the tertiles and was consistent with results at 5% density described in the main text.  For visualization, the rich clubs are 
displayed at the same level of k detailed for the FM group in Supplementary Fig 1.  
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Table A.8: Correlations Between Eigenvector Centrality and Clinical Pain in Fibromyalgia 
Patients 
 
 Brain Region (Node #) r-value p-value 
Positive Correlations L Primary Somatosensory Cortex (20) 0.409 0.010 
 R Primary Motor Cortex (21) 0.361 0.024 
 L Primary Somatosensory Cortex (23) 0.323 0.045 
 L Primary Motor Cortex (24) 0.358 0.025 
 L Primary Motor Cortex (27) 0.363 0.023 
 L Primary Somatosensory Cortex (30) 0.389 0.014 
 R Supplementary Motor Area (31) 0.369 0.021 
 R Primary Motor/Somatosensory Cortex (36) 0.468 0.003 
 L Primary Motor Cortex (37) 0.383 0.016 
 R Posterior Insula (43) 0.429 0.006 
 L Primary Motor/Somatosensory Cortex (45) 0.366 0.022 
 R Primary Motor/Somatosensory Cortex (46) 0.416 0.008 
 R Supramarginal Gyrus (48) 0.398 0.012 
 L Primary Motor Cortex/Operculum (55) 0.389 0.014 
 R Superior Temporal Gyrus  (62) 0.396 0.013 
 R Superior Temporal Gyrus    (63) 0.455 0.004 
 R Posterior Insula (67) 0.344 0.032 
 L Primary Motor Cortex/Operculum (70) 0.566 0.000 
 R Primary Motor Cortex/Operculum (71) 0.368 0.021 
 R Primary Motor/Somatosensory Cortex (72) 0.416 0.008 
 R Superior Temporal Gyrus  (238) 0.488 0.002 
Negative Correlations L Orbitofrontal Gyrus (78) -0.347 0.031 
 R Angular Gyrus (130) -0.366 0.022 
 L Superior Frontal Gyrus (138) -0.355 0.027 
 L Supplementary Motor Area (174) -0.327 0.042 
 R Mid Frontal Gyrus (196) -0.387 0.015 
 R Supramarginal Gyrus (204) -0.332 0.039 
 R Posterior Cingulate (221) -0.331 0.039 
 R Inferior Frontal Gyrus (241) -0.387 0.015 
 L Inferior Temporal Gyrus (262) -0.435 0.006 
 
Table A.8. Correlations Between Eigenvector Centrality and Clinical Pain in Fibromyalgia Patients. L, left; R, right. 
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Appendix B : Supplementary Figures and Tables 
 
	  
Figure B.1. Study Design. Our within-subjects crossover design had three phases: a baseline pain assessment and functional 
magnetic resonance imaging (fMRI) session #1, sham tDCS for five consecutive days followed by pain assessment and fMRI #2, 
and real tDCS for five consecutive days followed by pain assessment and fMRI #3. Sham and real tDCS phases were separated 
by a 7-11 day washout period (mean = 9.9 days).  
 
Table B.1: Clinical Results 
 
 Baseline (mean ± 
SD) 
Sham (mean ± SD) Real tDCS (mean ± 
SD) 
Clinical Pain 
Intensity (VAS) 
5.12 ± 2.30 4.08 ± 2.11 3.33 ± 2.84* 
McGill Total Pain 24.09 ± 15.08 18.67 ± 12.47 19.33 ± 15.30 
PANAS (Positive 
Affect) 
19.78 ± 5.99 17.82 ± 5.47 16.09 ± 6.41 
PANAS (Negative 
Affect) 
14.33 ± 3.39 15.36 ± 5.46 12.73 ± 3.58* 
 
Table B.1. Clinical Results. * Significantly different from baseline at p < 0.05 
	  
 
 
 
 
 
 
 
 
 
 
tDCS Study Design
Baseline Sham tDCS Real M1 tDCS
fcMRI #1 & fcMRI #2 & fcMRI #3 &
5x, once daily 5x, once daily
Clinical Pain Clinical Pain Clinical Pain
 Wash-Out
(mean= 9.9 days)
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Table B.2: Patient Characteristics 
 
ID Age VAS McGill PANAS 
 Positive Negative 
 B S R B S R B S R B S R 
1 34 3 5 2 11 18 14 NA NA NA NA NA NA 
2 46 5 6 8 37 33 55 30 19 14 16 20 14 
3 54 8 6 5 27 13 23 14 10 10 21 27 10 
4 37 4 4 3 36 16 27 20 20 30 15 16 11 
5 64 0 0 0 0 0 0 16 20 22 13 10 10 
6 56 4 3 0 37 42 22 13 13 14 11 10 10 
7 58 6.5 2 0 8 4 0 19 26 14 14 13 12 
8 52 6 2 3 31 27 24 29 24 23 10 10 10 
9 54 4 3 3 10 11 10 NA 10 10 NA 16 20 
10 40 6 7 7 NA 12 27 NA 15 10 NA 18 18 
11 45 7 5 2 21 16 4 19 16 13 12 10 10 
12 52 8 6 7 47 32 26 18 23 17 17 19 15 
 
Table B.2. Patient Characteristics. VAS, visual analog scale; PANAS, positive and negative affect scale; B, baseline; S, sham; R, 
real tDCS; NA, not available 
 
 
Table B.3: Baseline FC Predicts Subsequent Analgesia 
  
 Δ Clinical Pain (VAS) 
Sham - Baseline 
Δ Clinical Pain (VAS) 
Real tDCS - Sham 
Δ Clinical Pain (VAS) 
Real tDCS - Baseline 
L M1 – L VL 
Baseline FC 
r = -0.619 
p = 0.042 
r = -0.791 
p = 0.004 
r = -0.938 
p = 0.001 
L S1 – L anterior 
insula Baseline FC 
r = -0.671 
p = 0.024 
r = -0.774 
p = 0.005 
r = -0.961 
p = 0.001 
L VL – PAG 
Baseline FC 
r = -0.815 
p = 0.002 
r = -0.587 
p = 0.057 
r = -0.929 
p = 0.001 
 
Table B.3. Baseline FC Predicts Subsequent Analgesia. FC, functional connectivity; L, left; M1, primary motor cortex; VL, 
ventral lateral; S1, primary somatosensory cortex; PAG, periaqueductal gray 
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Figure B.2. Baseline FC Predicts Subsequent Analgesia. FM patients who had stronger FC at baseline between the left M1 seed 
and left VL thalamus, between left S1 and left anterior insula and between left VL thalamus and the PAG had greater 
improvement in clinical pain across sham and real tDCS. There were no regions that showed significant correlations between 
less FC at baseline and greater improvement in clinical pain.  The glass brain results for the left M1 seed are depicted at a voxel 
threshold of p<0.001.  
 
	  
Figure B.3. Main Effects of Sham and Real tDCS. A, The glass brain results for the left VPL thalamus seed are depicted at a 
voxel threshold of p<0.001 for the baseline > sham and sham > baseline contrasts. Significant results were only found for 
baseline > sham (see Table 3.2 main text). B, The glass brain results for the left VLL thalamus seed are depicted at a voxel 
threshold of p<0.001 for the sham > real tDCS and real tDCS > sham contrasts. Significant results were only found for sham > 
real tDCS (see Table 3.4 main text). 
Baseline FC Predicting Subsequent Analgesia
Left M1 seed
Positive Correlation Negative Correlation
Main Effect of Sham tDCS
A. Left VPL thalamus seed
Baseline > Sham Sham > Baseline
Main Effect of Real tDCS
A. Left VL thalamus seed
Sham > Real Real > Sham
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Table B.4: Main effect of Real tDCS compared to Baseline 
 
Seed 
FC Region 
MNI coordinates 
(x y z) 
T Cluster size Cluster p-value 
Baseline > Real       
L VPL thalamus       
L IPL -46 -50 34 5.40 239 0.041 FWE 
PAG       
PCC -12 -36 38 5.98 354 0.007 FWE 
Baseline < Real       
N.S.       
 
Table B.4. Main effect of Real tDCS compared to Baseline. FC, functional connectivity; VAS, visual analog scale; L, left; R, 
right; VPL, ventral posterior lateral; IPL, inferior parietal lobule; PAG, periaqueductal gray; PCC, posterior cingulate; MNI, 
Montreal Neurological Institute 
	  
	  
Figure B.4. Real tDCS decreases FC compared to baseline. A, Decreased connectivity between the left VPL (seed in white) and 
IPL after real tDCS. Plots show changes in FC between baseline and real tDCS for each FM patient. B, Decreased connectivity 
between the PAG (seed in white) and PCC after real tDCS. VPL, ventral posterior lateral; IPL, inferior parietal lobule; PAG, 
periaqueductal gray; PCC, posterior cingulate; L, left; R, right; FC, functional connectivity (fisher transformed r-values). 
 
Table B.5: Correlations between change in FC and change in clinical pain (VAS) for baseline vs 
real 
 
Seed 
FC Region 
MNI coordinates 
(x y z) 
T Cluster size Cluster p-value 
L S1        
L SMA -2 4 52 6.98 200 0.013 FWE 
 
Table B.5. Correlations between change in FC and change in clinical pain (VAS) for baseline vs real. FC, functional 
connectivity; VAS, visual analog scale; L, left; R, right; S1, primary somatosensory cortex; SMA, supplementary motor area; 
MNI, Montreal Neurological Institute 
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Figure B.5. Correlation between change in FC and change in clinical pain after real tDCS. Patients with reduced FC between 
the left S1 (seed in white) and left SMA had greater reductions in clinical pain after real tDCS compared to baseline. S1, primary 
somatosensory cortex; SMA, supplementary motor area; VAS, visual analog scale; L, left; R, right; FC, functional connectivity 
(fisher transformed r-values). 
 
 
Table B.6: Correlations between change in FC and change in clinical pain (McGill) for real vs 
sham tDCS 
 
 Δ McGill Clinical Pain  
Real tDCS - Sham 
L VPL – R posterior insula  
Real - Sham FC 
r = 0.752 
p = 0.008 
L VPL – M1/S1 
Real - Sham FC 
r = 0.602 
p = 0.05 
L VL – R posterior insula 
Real - Sham FC 
r = 0.648 
p = 0.031 
 
Table B.6. Correlations between change in FC and change in clinical pain (McGill) for real vs sham tDCS. FC, functional 
connectivity; L, left; VPL, ventral posterior lateral; M1, primary motor cortex; S1, primary somatosensory cortex; VL, ventral 
lateral 
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Figure B.6. Correlations between changes in functional connectivity and changes in pain. A, The glass brain results for the right 
VPL thalamus seed are depicted at a voxel threshold of p<0.001. Significant results were only found for correlations between 
reductions in connectivity and reductions in clinical pain after sham tDCS (see Table 3.3). There were no significant correlations 
between increases in connectivity and reductions in clinical pain. B, The glass brain results for the left VPL thalamus seed are 
depicted at a voxel threshold of p<0.001. Significant results were only found for correlations between reductions in connectivity 
and reductions in clinical pain after real tDCS (see Table 3.5). There were no significant correlations between increases in 
connectivity and reductions in clinical pain. 
 
 
 
	  
Correlations between change in FC and change in pain (Sham - Baseline)
A. Right VPL thalamus seed
Positive Correlation Negative Correlation
Correlations between change in FC and change in pain (Real - Sham)
A. Left VPL thalamus seed
Positive Correlation Negative Correlation
